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Prenatal substance exposure such as alcohol, nicotine, and opiates is known to
modulate autonomic regulatory function during sleep, and to decrease arousability and
spontaneous movements (SM). SM during sleep may reflect a protective mechanism for
immature patterns of arousals. Neurodevelopmental compromise in sleep and arousal
systems may underlie sudden infant death syndrome (SIDS) risk in which infants expire
during sleep. Previous studies from our laboratory found abnormal patterns of neonatal
arousal, sleep fragmentation, and deficits in sleep-related SM in infants with prenatal
alcohol exposure. In this study, prenatal exposure to methadone was hypothesized to
disrupt the development of sleep and arousal neural circuitry, which have been found for
other high-risk samples. Neonatal Abstinence Syndrome (NAS) is a common
consequence of prenatal methadone exposure that may appear within 24 - 72 hours postbirth, and is known to disrupt sleep due to hyperarousability. As a secondary hypothesis,
the neonatal age (day 1 or 2 of life) was expected to affect infant sleep and arousal

outcomes in methadone-exposed neonates particularly on day 2 when NAS symptoms
increase. Additionally, single nucleotide polymorphism (SNP) in the catechol-O-methyltransferase (COMT) gene was found to associate with the severity of NAS in our previous
study. NAS severity has been associated with sleep disorders. Therefore, the second
hypothesis of this thesis study is that the minor allelic variants (AG/GG) of the COMT
gene previously identified as protective of NAS severity may also associate with better
sleep organization and more robust SM than the carriers of the AA genotype. Rural,
disadvantaged Caucasian mothers and infants (N=58 dyads: methadone=37,
comparison=21) were recruited from multiple narcotic treatment sites and prenatal clinic
at Eastern Maine Medical Center (EMMC). Mothers were interviewed to determine
demographics, psychiatric status, and substance abuse history during the 3rd trimester. Biweekly maternal urinalysis screens and neonatal meconium were applied to verify comorbid alcohol, tobacco, and other drug use. Finnegan scores determined symptoms of
withdrawal in opioid exposed newborns. Videosomnographic recordings of behavioral
states were collected in the newborn nursery of EMMC overnight, and recordings
between 2400-0500h were analyzed for frequency and duration of sleep, wake, arousal,
and SM. Saliva samples for genetic study was collected using OrageneTM kits. Results
from behavioral state analysis (n=50) showed that methadone-exposed neonates were
significantly hyper-aroused and crying more on both day 1 and 2 of life (p<.05); and both
the frequency and duration of these parameters increased significantly in the methadoneexposed neonates on day 2 of life, as expected. In the genetic study (n=20), neonates with
NAS protective AG/GG genotypes showed better behavioral sleep, fewer arousals, and
robust SM than infants with NAS risk AA genotype (p<.05). These findings support

evidence of sleep fragmentation in the exposed neonates that is exacerbated by the
passage of time since birth when withdrawal symptoms compound the intensity of sleep
disturbance and infant distress. Consistent with other findings from other SIDS-risk
samples, these findings indicate that arousal and SM regulation may be disrupted in
methadone-exposed neonates, suggesting that prenatal methadone may increase risk for
SIDS.
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CHAPTER 1
INTRODUCTION
Misuse of prescription opiates such as Oxycontin, Percocet, and Vicodin has
increased in the past decade and is alarming because a high percentage of the opiate
dependent population consists of women of childbearing age (i.e., 18 to 34 years old)
which has resulted in a sharp increase in the number of newborns with prenatal opiate
exposure (Office of National Drug Control Policy, 2011). These newborns are at high risk
for developing neonatal abstinence syndrome (NAS), which is a marker for stress
abstinence likely to surface within 24 to 72 hours postpartum (Jones, Kaltenbach, Heil,
Stine, Coyle et al., 2010). Maine is identified as one of the states with the highest opiate
addiction, according to a recent report by the Substance Abuse and Mental Health
Services Administration (SAMHSA, 2012), thus making the prescription opiate abuse a
major concern of the state of Maine. Our laboratory has investigated pregnancy and early
development of methadone-exposed infants born in Maine by assessing cognition and
learning (Logan, Hayes, Brown, Tisher, Paul, & Krishnan, 2009), maternal depression
and infant temperament (Heller, 2012), variations in the degree of NAS in relation to
maintenance therapy type (Pritham, Paul, & Hayes, 2012) and genetics (Wachman,
Hayes, Brown, Paul, Harvey-Wilkes et al., 2013). This thesis study will investigate signs
of potential neural circuitry deficits in utero by analyzing the sleep-wake continuity and
arousal regulation of methadone-exposed neonates within the first 2 nights of life before
NAS appears.
NAS is characterized by central nervous system (CNS) hyperirritability and
dysfunction in the autonomic nervous system, gastrointestinal tract, and respiratory
1

system, and one major characteristics of this condition is sleep disruption due to
hyperarousability (Finnegan & Kaltenbach, 1992). Proper sleep regulation is essential
especially during the neonatal period when maximum neural proliferation or expansion of
neural network occurs, particularly during rapid eye movement (REM) sleep (Mirmiran,
Maas, & Ariagno, 2003). An infant’s inability to maintain sleep quality has been
associated with sudden infant death syndrome (SIDS) (Kinney, 2005; Sawaguchi, Franco,
Kadhim, Mori, Ito, Taki, Sawaguchi, & Kahn, 2014).
SIDS has been associated with prenatal neural insult in sleep areas of the developing
brain in infants who have had prenatal alcohol exposure (Kinney, 2005). Our laboratory
has reported that prenatal exposure to alcohol was associated with increased sleep
fragmentation, defined as increased arousals during sleepand also suppressed SM during
sleep (Troese, Fukumizu, Sallinen, Gilles, Wellman, Paul, & Hayes, 2008). This pattern
of sleep disturbance is associated with the development of sleep deprivation. In a study of
premature infants who have a significantly higher than average risk of SIDS, our
laboratory has found that arousals and awakenings eventually decrease with increasing
days of sleep fragmentation, as would SMs (Hayes, Akilesh, Fukumizu, Gilles, Sallinen
et al, 2007). Hence, SIDS risk groups such as premature births, and infants with prenatal
exposure to alcohol were both associated with poor sleep quality, increases and eventual
decreases in arousals and awakenings, and suppressed activation of SM. This thesis study
is designed to examine another prenatal exposure, the synthetic opioid methadone, which
has similarly been associated with increased SIDS rates (Hunt, 2008). The thesis study
will investigate the characteristics of sleep quality, sleep-related arousals, and SM

2

patterning in neonates who have been prenatally exposed to the opioid methadone taken
daily by the mother for opioid dependence.
1.1. Neuropharmacology of Opioid Addiction
The next section will examine the fundamentals of opioid addiction and
dependence to provide background for neonatal dependence in NAS. Koob (2008)
describes drug addiction as a disorder governed by motivation, which is modulated by the
reward circuitry of the brain. This process begins with elevated motivation to experience
the hedonic or rewarding influence of the drug (impulsivity) followed over time by the
desire to avoid the anhedonia (i.e., lack of pleasure) and unpleasant consequences of
withdrawal (compulsivity). According to Koob, common motivation-driven cyclical
characteristics of addiction include craving, tolerance, dependence, withdrawal, and
relapse; and these processes are mediated by the mesoaccumbens dopamine (DA) system,
in which mesolimbic DA is projected from the ventral tegmental area (VTA) primarily to
the nucleus accumbens (NAc), as well as the medial prefrontal cortex (mPFC), amygdala,
and ventral pallidum. Repeated exposure to drugs eventually alters this neurocircuitry
causing both synaptic-level and systems-level plasticity.
Neuroadaptation is the transformation of reward to a habitual state from drug
related activation of this system. In this thesis, it is proposed that early developmental
changes in drug-related reward circuitry might reduce children’s reward level by setting a
higher bar for eliciting a hedonic effect. This change results in the activation of aversive,
or anti-reward, circuitry (Koob, 2008). Koob’s theory of the underlying mechanism of
addiction indicates that withdrawal symptoms frequently occur as an aftermath of drug
dependence. Among drugs with high potency for dependence, are opiates.
3

Opioid prescription medications leading to dependence and methadone
replacement therapy is the background of mothers in the current study in which the
developing fetus is exposed to opioids through maternal use during pregnancy. Maternal
opioid medications, such as methadone, affect the developing fetus through placental
transfer and membrane changes that improve opioid absorption during the last trimester.
Fetuses exposed to opioids after thirty-four weeks gestational age are more likely to
develop an abstinence syndrome than those born earlier (Barr, McPhie-Lalmansingh,
Perez, & Riley, 2011). In infants, withdrawal is a similar process as that observed in
adults. Therefore, prenatal exposure to drugs of abuse followed by neonatal withdrawal
may pose significant neuroadaptive consequences to the developing brain.
Opioids are psychoactive chemical substances that can exert analgesic and
rewarding effects by binding to opiate receptors, which are distributed widely in different
areas of the brain. In a recent review, Waldhoer, Bartlett, and Whistler (2004) reported
that opioid receptors are primarily located in the central (CNS) and peripheral nervous
system (PNS) as well as in the gastrointestinal tract (GI).
Four major types of opiate receptors have been identified: mu (MOR-OP3), delta
(DOR-OP1), kappa (KOP-OP2), and nociception receptors (NOP-OP4), according to
Stein, Schäfer, and Machelska (2003) as well as Fine (2004). These authors further
specify the locations and respective functions of these receptors. The primary locations of
DOR-OP1 are the pontine nuclei, amygdala, olfactory bulbs, and deep cortex of the brain.
This receptor has two subtypes – delta1 and delta2 – and is believed to be responsible for
eliciting analgesia, antidepressant effects, convulsion effects, and physical dependence. It
is also suspected to play a role in mu-opioid receptor-mediated respiratory depression or
4

hypoventilation. KOR-OP2 is found in the hypothalamus, periaqueductal gray, and
claustrum of the brain, and also in the substantia gelatonisa of the spinal cord. The
primary functions of these receptors are analgesia, anticonvulsant effects, dissociative and
deliriant effects, diuresis, dysphoria, miosis or pupil constriction, neuroprotection, and
sedation. Three currently identified subtypes of MOR-OP3 are mu1, mu2, and mu3. These
receptors are located in the areas of brain such as cortex, thalamus, striosomes,
periaqueductal gray, and rostral ventromedial medulla, in the substantial gelatinosa of
spinal cord, in the intestinal tract, and the peripheral sensory neurons. The primary
functions of these receptors are subtype-specific such that mu1 functions to elicit
analgesia and physical dependence; mu2, is responsible for respiratory depression, miosis,
euphoria, reduced GI motility, and physical dependence; and mu3 for vasodilation. The
NOP-OP4 receptors are located in the areas of brain namely cortex, amygdala,
hippocampus, septal nuclei, habenula, and hypothalamus, and in the spinal cord.
These endogenous opioid systems are crucial in modulating the sensation of pain
and pleasure (Fine, 2004). Prolonged, repeated exposure to narcotics derived from nature
as well as synthetic opioids may compromise this system such that the body becomes
sensitized to the effects of opioids and requires higher levels of opioids to elicit an
adequate amount of effect. This could result in the development of opiate dependence.
Therefore, the effect of synthetic opioids is associated with a rewarding, pain-free, or
even pleasant experience (Fine, 2004; Stein et al., 2003; Waldhoer et al., 2004).
1.1.1. Neonatal Outcomes of Prenatal Exposure to Opioids. Prenatal exposure to
substances of abuse such as opioids has been associated with less optimal neonatal
outcomes. Opiate addiction is typically polydrug abuse where multiple drugs are used.
5

The most common co-occurring substances are alcohol, tobacco, and marijuana. The
sociodemographic population at greatest risk for opiate addiction is more likely to use
other drugs of abuse, especially tobacco, alcohol and marijuana (Hayes, Brown,
Hofmaster, Davare, Parker, & Raczek, 2002). Patrick et al. (2012) report that infants with
prenatal opioid exposure show significant likelihood for respiratory diagnoses, low birth
weight, feeding difficulties and seizures. In a recent report, Negrato and Gomes (2013)
found that low-birth weight was likely a consequence of intrauterine insults such as
maternal substance abuse. Low-birth weight is associated with health complications such
as breast and testicular cancer, osteoporosis, cardiac hypertonicity, lack of alertness, and
instability of mood in adulthood. These findings in combination with the consistent
prevalence of low-birth weight among opiate-exposed infants are some of the examples
of concern that make the investigation of prenatal opiate exposure-related developmental
outcomes crucial to the health of at-risk children.
Prenatal exposure to opiates, often in combination with cocaine, has been associated
with early life neurodevelopmental adversities including infant mortality such as Sudden
Infant Death Syndrome or SIDS (Burns, Conroy, & Mattick, 2010). Conradt, Sheinkopf,
Lester, Tronick, LaGasse et al. (2013) found prenatal opioid exposure to be associated
with the highest level of heart rates and the lowest level of respiratory sinus arrhythmia
(RSA) which indicate suboptimal autonomic functioning. Janssen, DiPietro, Elko,
Williams, Milio, and Velez (2012) have studied RSA during fetal life. RSA is a variation
in heart rate that occurs naturally during a breathing cycle such that heart rate increases
during inhalation and slows down during exhalation. Such a pattern of heart rate is
termed heart rate variability or HRV. In the same study, the opiate-exposed fetuses post
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birth showed more non-optimal reflexes and stress/abstinence signs, poorer quality of
movements and increased hypertonicity during a sustained visual task using the NICU
Intensive Care Unit Neurobehavioral Scale (NNNS; Lester, 2004). These results indicate
that autonomic nervous system (ANS) dysfunction is of concern in infants born with
prenatal exposure to opiates and cocaine, and the developmental outcomes of these
infants in early life is neurobehaviorally poorer than comparison samples.
1.1.2. Treatment of Opioid Addiction During Pregnancy. A current standard of
care for treating opiate dependence during pregnancy is the narcotic treatment program
(NTP). Clinically controlled substitutes such as buprenorphine or methadone are used to
prevent opioid drug seeking and to promote harm reduction during pregnancy (Patrick et
al., 2012). For this thesis, all mothers in the methadone-exposed group were enrolled in
the NTP and maintained on methadone.
Lugo, Satterfield, and Kern (2005) state that methadone is a lipophilic, synthetic
opioid that is a µ-opioid receptor agonist, a weak NMDA agonist, and inhibitor of the
production of cyclic adenosine monophosphate (cAMP) at the cellular level. Methadone
accumulates at tissue binding sites, and is released into plasma during redistribution. This
contributes to a significantly longer half-life (24 hours) or duration of influence compared
to its counterparts in addition to being cost effective, which makes it an ideal substance
for opiate replacement therapy (Jones et al., 2010). Methadone is valued for its qualities
to exhaust cravings for opiates for a relatively longer period of time, stop physiological
withdrawal symptoms, and prevent the euphoric effect associated with illicit opioid abuse
(Kreek, 2000; Ward, Drover, Hammer, Stemland, Kern et al.,2014). Methadone is also
considered safer, as proposed by Jones, O'Grady, Malfi, and Tuten (2008), for pregnant
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opiate-dependent women and their fetus in comparison to continued prescription
painkiller or heroin abuse because the treatment provides them with consistency in daily
opiate doses as opposed to irregular binge and withdrawal cycles that are characteristics
of street narcotic abuse. Another advantage of being in treatment, as mentioned by Jones
et al., is that the use of other substances of abuse is monitored through random drug
screens that occur at least monthly. The pharmacological testing performed by Affiliated
Laboratories, Inc., of Bangor, Maine included urinary drug screens (UDS) for
benzodiazepines, cocaine, methylphenidate, cocaine metabolites, cannabinoids, lysergic
acid diethylamide, buprenorphine (subutex), methadone and methadone metabolites,
oxycodone, barbiturates, cotinine, and other drugs during pregnancy and postnatally for
the methadone-exposed group mother of the present study. Also, screening for alcohol
was done by using breathalyzers at the time of UDS. However, it is not always possible to
trace in-utero alcohol exposure through theUDS alone. Therefore, an exposure to alcohol
was also ascertained through careful clinical interview with standard methods that were
included in this thesis.
Nanovskaya, Nekhayeva, Hankins, and Ahmed (2008) report that the placenta is
permeable to maternal use or consumption of substances such as alcohol, tobacco, and
opioids and that the rate of fetal exposure to opioids is the highest during the 3rd trimester
when the placental barrier becomes highly permeable, thus, increasing the concentration
of penetrated substances in the fetal environment. The underlying mechanism of this
increased permeability during the 3rd trimester is purported to result from the readiness of
the fetus to absorb as many nutrients as possible from maternal blood in order to ramp up
the growth process in preparation for the upcoming birth. On the other hand, the same
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mechanism also may cause the maternal dose of methadone to permeate the placental
barrier more readily, and this may result in the fetus becoming an additional consumer of
the maternal dose, which may cause an earlier-than-usual experience of withdrawal in
mothers. Therefore, Logan, Brown, and Hayes (2013) suggest a careful maternal dose
management to be recommended to the methadone maintained mothers especially during
the 3rd trimester of gestation by following the most practiced paradigm (i.e., split-dose as
opposed to once-a-day dose) in order to increase methadone half-life and avoid potential
repeated fetal withdrawal cycles that may cause severe neurobehavioral consequences
including fetal mortality. Besides all the advantages of methadone treatment for opiate
dependence during pregnancy, effects of prenatal exposure to methadone on the
development of humans from fetal stage throughout the lifespan are relatively unknown.
The following section presents some of the neurodevelopmental outcomes of prenatal
exposure to methadone.
1.1.3. Neurodevelopmental Consequences of Methadone Exposure. In order to
fully comprehend the actual effect of methadone on neonates, taking into consideration
the outcomes of both animal and human studies are equally importance because while
animal studies ideally provide an insight into specific biobehavioral effects of methadone
exposure, human studies present an opportunity to investigate those isolated effects in
association with environmental factors to broaden our understanding of the implication of
prenatal methadone exposure. Therefore, this thesis study attempted to look into potential
neurodevelopmental impact of methadone exposure by examining the sleep state
organization of the exposed neonates.
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Due to the complexity of human substance exposure in-utero resulting from a
highly frequent trend of poly-drug abuse among opiate-addicted pregnant women, it is
not easy to replicate an animal model of methadone exposure, and the results may face
translational controversies. However, carefully designed studies such as the one by
Hutchings, Zmitrovich, Church, and Malowany (1992) using mouse pups showed dosedependent neurobehavioral consequences of methadone exposure in those mouse- pups at
22 days of age where high dose pups demonstrated less restfulness, disrupted rhythmicity,
and poor state regulation as shown by increased state lability indicating dose-specific
neurodevelopmental abnormalities in comparison to low-dose methadone and nonmethadone pups.
A classic study by Guo, Enters, McDowell, and Robinson (1990) primarily
investigated the effect of methadone on the neurotransmitters cholinergic, noradrenergic,
dopaminergic, and serotonergic neurons, which are crucial for optimal
psychophysiological regulation in vertebrates. An osmotic minipump was used to
administer maternal methadone. The rats were impregnated naturally by placing male and
female rats together in the same cages. On the 8th day of gestation, two groups of
pregnant rats were subcutaneously administered either methadone or sterile water. The
methadone-exposed pups were postnatally injected with naloxone in order to confirm
methadone dependence. Then 4-day old pups were sacrificed and analyzed for the
neurotransmitters of interest. Results indicated sex-related differences in the brain regionspecific neurotransmitter content. The most important finding of this study was the
similar reduction of striatal acetylcholine content in both male and female pups
suggesting that prenatal methadone exposure may impair the stress regulatory system in
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infants of both genders equally. These researchers further demonstrated the effect of
prenatal methadone exposure on central cholingergic neuronal activity, delays in the
development and expression of striatal cholinergic neurons, and similar effects also on
the dopamine, norepinephrine, and serotonin systems.
Robinson and Kolb (1997) expanded their approach to examine the impact of
perinatal exposure to methadone on neurotransmitters more closely by using ratio of
neurotransmitters to their corresponding metabolites during both perinatal and postnatal
exposure to methadone. Pregnant rats were implanted with osmotic minipumps
containing either methadone hydrochloride (initial dose, 9 mg/kg/day) or sterile water on
day 7 of gestation. Their offspring were cross-fostered so that they were exposed to
methadone prenatally and/or postnatally. Then those pups were analyzed for dopamine
(DA), norepinephrine (NE), serotonin (5-HT), and their metabolites in relation to their
metabolites (i.e., 3,4-dihydroxyphenylacetic acid (DOPAC) for DA; 3-methoxy-4hydroxyphenylglycol (MOPEG) for NE; and 5-hydroxyindoleacetic acid (5-HIAA) for 5HT) on day 21. The results indicated gender specific differences in the disruptions of the
dopaminergic, noradrenergic, and serotonergic activity in a brain region. Males exposed
to methadone postnatally showed reduction in the ratio of the DA metabolite DOPAC to
DA in the frontal cortex, and this effect was not observed in the striatum. The ratio of
MOPEG to NE in the hippocampus was increased significantly in males exposed to
methadone prenatally. A slight increase in the striatal and parietal cortical 5-HT
metabolite 5-HIAA was observed in rats exposed to methadone postnatally but there was
no interaction between the ratios of 5-HT to its metabolite. The authors concluded that
the effects of methadone exposure might be dependent on the developmental stage at
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which exposure occurred and not so much on the neonatal withdrawal per se, and that
changes in activity of these three neurotransmitter systems may contribute to the effect of
perinatal methadone on the activity of other neurons.
Putting their findings into perspective, Robinson (2000) consolidated a review of
contemporary animal models of opioid exposure including methadone and reported that
even though opiate replacements such as buprenorphine or methadone are considered
non-teratogenic (i.e., not harmful to fetus) and preventative of repeated cycles of in utero
withdrawals, there is consistency in the finding of disruption of cholinergic system
development, particularly in the striatum of infant animals prenatally exposed to opioids.
Such effect has been deemed surpassable with an increase in postnatal cholinergic
neuronal activity, but even though acetylcholine (ACh) content and the expression of
choline acetyltransferase protein and mRNA are reduced in the early postnatal period by
prenatal opioid exposure in the rats, the activity of the cholinergic neurons remains
disrupted, with a large increase in ACh turnover rate suggesting that the chances of
overcoming cholinergic system deficit is low. One potential mechanism involved in this
phenomenon is related to atypical changes in the expression of nerve growth factor
(NGF), a neurotrophin known to influence the development of cholinergic neurons,
which has been found to be reduced by opioid exposure (Wu, Hung, Shen, Chen, Chang
et al., 2014). It is proposed that similar mechanisms are at work in methadone-exposed
infants leading to abnormal cell growth and migration, increasing the risk for
neurodevelopmental deficits.
Unlike animal models, human exposure to maternal use of methadone is much
more complicated due to the consistently documented issue of co-occurring multidrug use
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in addition to clinical methadone. Therefore, the study of the nature of prenatal exposure
to substances of abuse must rely on urinalysis screens that are merely a snapshot of recent
exposure for most substances, with the exception of cannabis and opioids, which can
persist for several weeks after ingestion (Katz & Fanciullo, 2002) Methadone dose and
dose change throughout pregnancy is determined through the medical records but
additional use is documented through random, monthly urinalysis. Since alcohol
exposure related to maternal use is known as a profound teratogen (Riley, Infante, &
Warren, 2011), determining dosage and timing of exposure is particularly difficult. State
of the art method in this area relies on maternal self-report using well-established alcohol
use instruments.
Functional consequences of prenatal exposure to opioids is evaluated through
neonatal neurological (imaging and motor testing), neurobehavioral [NICU Network
Neurobehavioral Scales (NNNS)] and neurocognitive (EEG, and event related potential
or ERP) assessments, and longitudinal postnatal behavioral observations to investigate
the effect of methadone, and such methods bring along controversies regarding potential
confounding variables. With an increase in the NAS incidence in the past decade, there is
a concern that prenatal methadone exposure may increase NAS severity (Jones et al.,
2010) and may compromise both pre and postnatal development, the latter primarily
related to CNS consequences of prolonged withdrawal, and iatrogenic effects of
replacement opioid medications.
Fetal neurobehavior can be viewed as an early marker of the developing nervous
system, and any in utero insult such as opioid exposure to this system may represent a
threat to the neural development of the fetus (Nijhuis, 2003). Even though opiate
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replacement therapy is a safer substitute for narcotic addiction, controversies about
whether they are safe for fetal neurodevelopment continue. Therefore in an attempt to
investigate the nature of impact buprenorphine or methadone may have on fetal
neurobehavior, Janssen et al. (2011) recorded fetal heart rate (FHR) and fetal movement
of 17 opioid-dependent pregnant women maintained on replacement therapy with either
buprenorphine or methadone. This demographically similar sample was drawn from the
Johns Hopkins Bayview Medical Center-based multidisciplinary treatment care facility
called the Center for Addiction and Pregnancy. Data were recorded at different time
points (i.e., 24, 28, 32, and 36 weeks) of gestation by using ultrasound for heart rate and
actigraphy for movement. The results showed that acceleration of fetal heart rate (a
measure to assess HR variability) during 24 and 28 weeks of gestation was significantly
greater for fetuses in the buprenorphine group with no acceleration at all for the
methadone-exposed group during the recording period. Additionally, the methadoneexposed group showed significantly suppressed fetal movement in comparison to the
buprenorphine group suggesting that methadone may have adverse neurobehavioral
consequences in growing fetuses.
In another study, Coyle, Salisbury, Lester, Jones, Lin, Graf‐Rohrmeister, and
Fischer (2012) assessed the effect of methadone versus buprenorphine exposure on
neonatal neurobehavior on 39 full-term infants at 3, 5, 7, 10, 14-15 and 28-30 postpartum
days by using the Neonatal Intensive Care Unit (NICU) Network Neurobehavioral Scale
(NNNS), a standard measure of infant neurobehavioral development. The results revealed
in favor of buprenorphine with buprenorphine-exposed infants showing significantly
fewer stress-abstinence signs, less hypertonia, better self-regulation, less excitability, less
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over-arousal, and less handling need to maintain a quiet alert state in comparison to
prenatally methadone-exposed infants (Coyle et al., 2012). Additionally, the infants who
began NAS treatment at an older age demonstrated significantly higher self-regulation
scores, and the least amount of average excitability and hypertonia. The results suggest
that methadone may be less optimal for neonatal neurobehavioral development.
In the post-neonatal period, prenatal opiate exposure seems to pose a threat to
neuronal growth as demonstrated by Hu, Sheng, Lokensgard, and Peterson (2002), who
report that prenatal opiate exposure is associated with increased programmed cell death
(i.e., apoptosis) in human microglia and neurons. Neuronal apoptosis is known to be
important for the learning process and it functions by allowing for unused neurons to die
so that active neurons get proper environment to migrate to specific locations according
to the type of learning that has occurred. However, excessive increase of neuronal
apoptosis could indicate deficits in the brain white matter that may interfere with
appropriate learning processes, resulting in cognitive and behavioral dysfunctions.
Expanding this finding, Walhovd, Watts, Amlien, Woodward, and Woodward (2012)
examined the early cerebral connective tract development of infants born to methadonemaintained mothers and comparison infants by using diffuser tensor imaging with an
assumption that the methadone-exposed infants (n=15) show signs of lower neural tract
maturation than comparison infants (n=7). The outcome variable was determined based
on the mean diffusivity where higher diffusivity was marked as a sign of less maturation
and myelination. All infants were scanned within 13 to 44 days post-birth by using a
General Electric Signa HDx 3T MR scanner, and all scanned sets were checked for
motion artifacts (i.e., EEG data resulted from unwanted movements during scanning), and
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the researchers analyzed the voxel-based statistical analysis of the mean diffusivity by
using the tract-based spatial statistics and permutation based statistics (Walhovd et al.,
2012). Diffusion tensor MRI (DT-MRI) is a non-invasive method to map the
characteristics of soft tissue in which the MRI or magnetic resonance imaging signal to
the random molecular motion of water molecules (diffusion) is sensitized by adding
‘diffusion encoding gradients’ to a standard MR pulse sequence (Jones & Leemans,
2011). The corpus callosum as well as eight major white matter areas was defined as
areas of interest, and inferior longitudinal fasciculus and superior longitudinal fasciculus
were selected as tracts of interest for analyzing the outcome difference. In order to match
the hypothesis of this study, higher level of diffusivity was expected in infants exposed to
methadone because high diffusivity has been associated with a sharp decrease in the brain
maturation as well as demyelination or decrease in myelination in both human and animal
studies. Supporting their hypothesis, the results of this study demonstrated that the
methadone-exposed infants tended to have higher diffusivity of the brain neural tracts
than the comparison group. These results were similar to many other human and animal
studies indicating delay or deficit in brain maturational process as a result of prenatal
insult, particularly opiate exposure as discussed in the article. The significance of this
study relies on identifying early markers of neural alterations that may be predictive of
cognitive and behavioral problems observed in existing studies pertaining to prenatal
opioid exposure (Walhoved et al., 2012).
Children with prenatal exposure to substances also tend to have difficulties with
attention in the later years. To investigate early detection of attention problems in
methadone-exposed infants, a study by Paul, Logan, Krishnan, Heller, Morrison et al.,
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(2014) from our lab used a subset of a sample from an ongoing longitudinal study to
assess infants’ habituation to auditory stimuli within 4-15, 16-32, and 33-120 days of
postnatal age. Habituation to novel stimuli is one of the markers for cognitive
development as it indicates an infant’s efficiency for learning new information, and is
measured by using the auditory oddball paradigm [a method used in electrocephalogram
(EEG) that involves the presentation of frequent auditory stimuli with a randomly
distributed novel high-pitched auditory stimulus presented occasionally throughout the
testing period to examine variability in the brain waveforms in response to frequent and
random stimuli] with primary focus on the amplitude and latency of peak-2 (P2) in
response to novel stimuli. Results revealed that there were no group differences in the P2
amplitude in the older groups as opposed to younger groups, indicating that postnatal
environmental buffers may moderate possible adverse consequences of methadone in the
long run, and the group difference observed during the youngest age range could have
resulted from the neonatal abstinence syndrome (NAS).
Another major pediatric health concern associated with prenatal exposure to
methadone is impairment of visual development. Hamilton, McGlone, MacKinnon,
Russell, Bradnam, and Mactier (2010) reported case studies of 20 of their pediatric
patients who were exposed to methadone in utero and referred to them for visual
anomaly. The authors used the measure of ophthalmic and orthoptic examination and
visual electrophysiology as seemed appropriate on an individual basis. Additionally, the
children’s case history and maternal urine toxicology were obtained for cross analysis.
The results revealed ophthalmic abnormalities including reduction in acuity (95%),
nystagmus (70%), delayed visual maturation (50%), strabismus (30%), refractive errors
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(30%), and cerebral visual impairment (25%) (Hamilton et al., 2010). Of the 20 patients,
60% had abnormal visual electrophysiology and one-fourth of the children showed
neurodevelopmental abnormalities associated with the visual anomaly. Most importantly,
79% of the nystagmus cases were treated for neonatal abstinence syndrome (NAS). These
results indicate that infants with in utero exposure to methadone are at high risk for visual
abnormalities, and NAS-treated babies are potential targets for nystagmus.
McGlone, Hamilton, McCulloch, Boulton, Bradnam, Weaver, and Mactier (2013)
expanded on the visual development of methadone-exposed infants in their study by
using flash visual evoked potentials (VEPs), an EEG method that elicits brain waveforms
upon the presence of flashed visual stimuli. The researchers recorded flash VEPs from
infants within 3 days of birth from 100 infants prenatally exposed to methadone, and 50
demographically matched comparison infants. The classification of VEP morphology
consisted of mature, typical, or immature, which were categorized based on the
amplitudes and implicit times of the major waveform components. Maternal history,
maternal and infant urine, and meconium toxicology were used to determine drug
exposure. The results revealed that maternal methadone-exposed infants were more likely
to form immature waveform and the peaks of such waveforms were smaller in overall
amplitude. More importantly, this effect persisted even after controlling for birth weight,
cigarette smoking, and excess in utero alcohol exposure indicating that methadone
exposure may affect visual anomaly in children and may need earliest possible attention
to their visual health. All these short- and long-term postnatal outcomes aside, the biggest
concern considering prenatal methadone exposure is NAS, which is experienced by many
methadone-exposed neonates.
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1.1.4. Neonatal Abstinence Syndrome (NAS). One persistent consequence of
prenatal methadone exposure is NAS, which surfaces within 24-72 hours post birth
(Finnegan et al., 1991). NAS is a constellation of stress abstinence symptoms resulting
from a physiological dependence to maternal use of opiates. In the clinical protocol
described in a report to The Committee on Drugs and The Committee on the Fetus and
Newborn by Hudak, Tan, Frattarelli, Galinkin, Green et al. (2012), NAS is characterized
to have symptoms of tremors, irritability, sleeping problems, high-pitched crying,
hypertonicity, poor feeding, stuffy nose, sneezing, yawning, gastro-intestinal
dysregulation, dehydration, sweating and seizures, which together are indicators of CNS
immaturity. NAS also poses a risk of neuromaturational deficits as manifested in the form
of seizures, poor weight gain, dehydration and general dysregulation because of its long
course of three to seven weeks with residual symptoms for six months or longer (Hayes
& Brown, 2012). About 50% to 70% of these infants need pharmacological intervention
(i.e., clonidine and/or phenobarbital) based on the severity of symptoms determined by
the Finnegan Neonatal Abstinence Severity Index (Janssen et al., 2013). However,
comparatively milder abstinence syndromes not requiring replacement medications have
been reported with prenatal exposure to cocaine, nicotine, sedatives, barbiturates, SSRIs,
etc. during pregnancy (reviewed in Janssen et al., 2012).
Methadone-exposed infants tend to show variability in the profile of NAS - some
exposed neonates go home in 5 days whereas many stay for longer than 3 weeks (Jones et
al., 2010). In the clinical research, therefore, the length of hospital stay (LOS) is used as a
benchmark to assess the severity of NAS (Patrick et al., 2012). A few known causes of
such variability appear to be maternal methadone dose and gestational exposure to
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benzodiazepines (Pritham, Paul, & Hayes, 2012); higher overall drug dose before
delivery and gestational age (i.e., shorter gestation = shorter LOS) (Liu, Jones, Murray,
COOK, & Nanan, 2010); and allelic variants in the mu opioid receptor type 1 (OPRM1)
and catechol-O-methyl-transferase (COMT) genes (Wachman et al., 2013). In the genetic
study by Wachman et al. (2013), single nucleotide polymorphism (SNP) in the OPRM1
and COMT genes predicted NAS severity where AA genotypic variation in both genes
were associated with a higher severity of NAS and AG or GG genotypes served as
protective factors. Revisiting Koob’s theory of tolerance, tolerance results from an
enhanced physical ability to intake a substance without having withdrawal symptoms,
thus, reinforcing the reward system of the substance user to use more, which is a risk
factor for addiction. If that is true, then perhaps the neonates with the minor allelic
variants of the COMT SNP might be at risk for addiction due to enhanced tolerance to
opiates.
Taken together, it may be speculated that deficits in the CNS and ANS
maturational process associated with prenatal opiate and potentially comorbid substance
exposure. One way to investigate this possibility is by assessing sleep organization during
the neonatal period. The association of prenatal substance exposure to sleep, wake, and
arousal deficits has been established through previous studies in our lab in which
perinatal alcohol appeared to mediate the effect of methylxanthine on arousal regulation
of preterm apneic neonates (Hayes et al., 2007).
1.2. Ontogenic and Biological Bases of Sleep and Wake
Sleep is a ubiquitous phenomenon among vertebrates. The duration and intensity of
sleep are regulated by the interaction of homeostatic processes, in which the requirement
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for sleep builds during waking and is relieved by sleep, and circadian rhythm. According
to Stern, Parmalese, Akiyama, Schultz, & Wenner, (1969), this rhythm determines the
timing of the sleep/wake cycle according to an internal signaling system such as the
suprachiasmatic biological clock and external signals such as the light-dark cycle.
Circadian rhythm follows a diurnal sleep-wake pattern with 24-hour periodicity and this
periodicity is characterized by sustained wakefulness during the daylight and sustained
nocturnal sleep. Most adults’ sleep cycles follow this pattern and the onset and offset of
the sleep cycle is determined by an individual’s biological clock. For example, de
Benedictis, Larson, Kemp, Barston, and Segal (2007) suggest that individuals who are
prone to waking up early in the morning are likely to continue waking up at the same
time every day even if slightly sleep deprived. In mammals, sleep/wake regulation is
conducted in the basal forebrain, which is located adjacent to preoptic and supraoptic
levels of the hypothalamus and includes cholinergic cells as well as glutamatergic and
GABAergic neurons. Despite an ongoing debate on the optimal amount of sleep for an
adult, a common understanding is that a healthy adult sleeps about 7-8 hours a night for
optimal functioning during the day. However, multiple factors may play a role in the
timing, duration, and rhythmicity of sleep. The typical nocturnal sleep cycle in adults
consists of the oscillation of Rapid Eye Movement (REM) and Non-rapid Eye Movement
(NREM) sleeps, which generally repeat every 90 minutes (Roehrs, Carskadon, Dement,
& Roth, 2005). In an overview of the neurobiology of REM and NREM sleep, McCarly
(2007) characterizes REM sleep or paradoxical sleep as the stage when low amplitude,
high frequency EEG activity is present, muscle tone is extremely suppressed, and the
rapid ocular saccades occur. Most neuronal activity and dreaming are believed to occur
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during this stage. McCarly further describes NREM sleep to have specific EEG
oscillation called spindles (waxing and waning within the 12-15Hz sigma band frequency
range that lasts at least 0.5 seconds), delta wave (1-3Hz), and slow rhythms. In humans,
NREM sleep stage undergoes three different stages. The first stage (N1), also called
drowsy sleep, is characterized by oscillation of EEG activity from alpha waves having
frequency of 8-13Hz to theta waves of 4-7Hz, some muscle activity, and the slow rolling
of eyes with opening and closing moderately. Consciousness of the environment starts to
deplete. This stage typically lasts for about 1-7 minutes. The second stage (N2) is
characterized by the appearance of sleep spindles and K-complexes ranging from 1214Hz EEG wave frequency and lasts for 10-25 minutes. K-complexes are the largest EEG
frequency waves that consist of a large positive peak followed by another large negative
peak. Metcalf, Mondale, & Butler (1971) mention that these peaks do not appear in
infants until the age of 6 months. McCarly further describes that muscular activity
decreases even more at this stage of NREM sleep and consciousness of the environment
disappears completely. About 45-55% of adult sleep comprises this stage. The N2
gradually develops into the last stage (N3) of NREM sleep. This stage is called deep sleep
or slow-wave-sleep (SWS), which is characterized by 20-50% presence of the EEG delta
frequency waves of 0-4Hz and lasts for 20 to 40 minutes in the first cycle. In this stage,
the sleeper does not respond to many environmental stimuli. A typical adult sleep pattern
follows four or five cycles of N1 – N2 – N3 – N2 – REM per night. The majority (~80%)
of the first half of the nocturnal sleep cycle comprises NREM sleep and the most of the
second half is spent on REM sleep.
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Unlike adults, the sleep-wake cycles of neonates and infants are much shorter, and a
newborn tends to awake every 3-4 hours for feeding and physiological needs. This pattern
continues until the first few months with the majority of their time (12-18 hours a day)
spent asleep, and about two-thirds of this sleep time is spent on active or REM sleep
(Roehrs, et al., 2005). In a clinical review of fetal and neonatal sleep and circadian
rhythm, Mirmiran et al. (2003) propose that the origin of sleep and circadian rhythm may
develop during the last 10 weeks of gestation, and the sleep-wake pattern during the fetal
period is comparable to preterm infants at 30-40 post-conceptional ages. Major
characteristics of infant sleep include Active Sleep (AS) that is equivalent to REM sleep
in adults, Quiet Sleep (QS) similar to adult’s NREM, and indeterminate sleep (IS) that
has the elements of both AS and QS. Mirmiran et al. (2003) report in a review that AS
and QS could be differentiated as early as 32 weeks of gestational age even though the
majority of sleep cycle during this time is spent on IS. Scher, Johnson, and Davis (2005)
expanded this hypothesis through an EEG sleep study on a subset of 33 preterm infants at
25-30 weeks post-conceptional ages by recording over 2 to 3 hours of the sleep period.
The results produced by Polysomnography data revealed that the majority of these
neonates showed a sleep cyclic pattern of 68 + 19 minutes per bout, and the variability
ranged from 37-100 minutes per bout of sleep. Another noteworthy finding of this study
included individual variability in the cycle length but not in the state cyclicity, indicating
that onset of sleep cycle development is potentially in progress as early as 25 weeks of
gestation and the determining factor of the quality of sleep could be individually
different. Despite all the possible individual variability, it has been well understood that
continuous maintenance of sleep and circadian rhythm is essential for optimal daily
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functioning and prolonged deprivation of sleep caused by sleep disorders or some
biological condition has been known to have a cumulative effect on the psychobiology of
an individual.
1.2.1. Sleep Deprivation and Consequences. Although the neurobiological
phenomenon of sleep has been studied through research using both humans and animals,
most of the theories of sleep biology are derived from animal studies, and the
assumptions pertaining to sleep-related brain plasticity have been formed based on the
deprivation model, which is measured through behavioral observation as well as
histology (Hayes et al., 2002). The deprivation model refers to the method that assumes
an adverse outcome when the outcome is preceded by the deprivation of stimulus. In
sleep related brain development, for example, research primarily focuses on depriving
subjects of certain stages of sleep (e.g., REM) by presenting external stimuli (e.g., visual,
auditory, physical), and compares its impact on the relative brain region between
deprived and non-deprived subjects.
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Figure 1.1. Potential adverse psychobiological effects of sleep deprivation.
http://en.wikipedia.org/wiki/Sleep
Orzeł-Gryglewska (2010) suggests that prolonged sleeplessness can result in
impairment of perception, lack of concentration, difficulty with vision, decrease in
reaction time, diminished schematic thinking that is responsible for decisions-making,
and problems with optimal emotion regulation that can manifest as deteriorated
interpersonal responses and increased aggressiveness. Sleep deprivation was also
associated with the presence of micro-episodes of sleep during wakefulness that lead to
lower efficiency of task performance and increased number of performance errors, as
well as poor memorizing. These findings indicate that sleep deprivation may alter brain
circuitry involving cognitive, emotional, and physiological functioning, thus placing an
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individual with sleep deprivation at risk for adversities including a threat to personal
well-being (e.g., automobile accidents, aggressive outburst).
In infants, the consequences of sleep deprivation are even greater because sleep
deprivation has been found to lead to longer-than-usual duration of sleep and decreased
latency to REM sleep (Franco, Seret, Van Hees, Scaillet, Vermeulen et al., 2004) as well
as decreased sleep-related arousal that is believed to be a risk factor for SIDS in infants
(Kato, Franco, Groswasser, Scaillet, Kelmanson, Togari, & Kahn, 2003). In order to
measure the level of sleep deprivation and the consequent arousal deficits, Franco et al.
(2004) induced sleep deprivation and arousals on fourteen healthy infants of age 6–18
weeks arousals in a sleep laboratory. These infants underwent polygraphic recording
during a morning nap and an afternoon nap, and were sleep-deprived for 2 hours before
being allowed to fall asleep. Sleep deprivation was achieved by keeping the infants
awake for as long as possible beyond their habitual bedtimes. The results revealed that
most sleep characteristics were similar for the normal and sleep-deprived conditions,
except that the duration of the naps increased, whereas the latency of REM sleep and the
density of body movements decreased. During such sleep, these infants needed moreintense auditory stimuli for arousal compared with normal nap sleep. Additionally, sleep
deprivation was associated with a significant increase in the frequency of obstructive
sleep apnea episodes, especially during REM sleep, which is another risk factor for SIDS
(Hunt & Hauck, 2006).
In order to determine the characteristics of arousal from sleep of infants who
eventually died of SIDS, Kato et al. (2003) monitored sixteen infants some days or weeks
before they succumbed to SIDS. The comparison of polygraphic sleep recordings of those
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infants with matched control infants showed that the cortical arousals in SIDS infants
were significantly less frequent than in the control infants during both REM and nonREM sleep (p = 0.039) in both frequency (p = 0.017) and duration (p = 0.005) measures.
Interestingly, the infants who later died of SIDS had more frequent cortical activation
between 9:00 P.M. and 12:00 A.M. (p = 0.038), and fewer cortical arousals between 3:00
and 6:00 A.M. (p = 0.011). The results suggest that a deficient arousal processes in
infants may pose a risk of SIDS in infants.
The interaction among sleep deprivation, arousals, and SIDS appears rather complex
though because while arousal deficit due to sleep deprivation is associated with SIDS,
excessive arousability during sleep leads to sleep fragmentation, which is the predecessor
of sleep deprivation (Hayes et al., 2007, 2008). Therefore based on the several
documented associations among sleep fragmentation, deprivation, arousal deficit, and
SIDS, it appears that while optimal amount of arousal is adaptive, hyper- or hypoarousability may pose a risk for adverse post-natal outcomes. Therefore it is important to
understand the underlying mechanisms as well as the risk factors associated with these
sleep components.
1.2.2. Arousals and SM in Sleep. Sleep state organization is an essential marker of
CNS and ANS maturity, common features of which, according to Hayes et al. (2007),
include presence of arousals and SM during sleep periods in a cyclical fashion. Arousal
criteria have been controversial due to the lack of standard operational definition that can
be applied across studies. Vecchierini and Navalet (2002) state that the process of
differentiating awakenings from arousal is based on the polysomnographic and behavioral
state criteria in which awakening is believed to occur when behavioral markers such as
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quiet or restless, open eyes, grimaces, movements, and occasional cry are present.
Arousal in general is also defined as a physiological and psychological state of being
awake or reactive to stimuli, which is achieved through a symphonic process of the
reticular activating system in the brain stem, the autonomic nervous system, and the
endocrine system stimulation leading to increases in blood pressure and heart rate that
trigger sensory alertness, mobility, and readiness to respond (Robinson, 2000). A
locomotive feature called SM during sleep is another measure to assess arousal quality
during sleep in neonates. It is a sleep state dependent movement pattern predicted to
occur periodically in a 3-5 minute window. SMs, as adapted from Prechtl (1990), is
defined as writhing bodily movements, characterized according to amplitude and speed,
which may be small-to-moderate or slow-to-fast, extension of the extremities
(particularly the arms), and exhibiting an elliptical motion, making such movements
similar in writhing quality. SMs have been believed to be a “primitive” physiological
arousal system that offers autonomic protection in sleep during the neonatal and early
infancy period when arousal systems are immature (Hayes et al., 1993). SMs, thus, serve
a potential primitive and protective arousal regulatory mechanism and their effect is to
restore airway openness and to up-regulate cardiorespiratory cycles of the medullary
circuitry (Hayes et al., 2007). Franco, Kato, Richardson, Yang, Montemitro et al. (2010)
state that the primary function of arousal from sleep is to allow sleep to continue in the
face of endogenous or exogenous stimuli that normally elicit responses during
wakefulness and also permit awakening. Thus, arousal bears an adaptive mechanism.
1.2.3. Substance Exposure, Sleep, and Arousal System. Abnormal sleep
architecture including sleep apnea is common in substance dependence and withdrawal.
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The medullary circuitry modulates autonomic tone, sleep, and arousal systems and
develops quickly in the first few months of postnatal life. However, infants exposed to
high levels of neurotoxic substances, including opiates, alcohol, and tobacco, often
exhibit neural circuitry abnormalities particularly in the brainstem region (Kinney, 2005).
As infant gestation advances, an emerging coupling mechanism of cardiac and somatic
functioning becomes increasingly prominent and is considered a function of innervation
of the autonomic nervous system (DiPietro, 2001). Reduced baseline heart rate and
depressed respiration have been found in methadone-exposed infants compared to nonexposed neonates along with significant differences in fetal cardiac-somatic coupling
(movement-heart rate), fetal motility, and the variability of heart rate patterns in
methadone-exposed neonates (Janssen et al., 2009), which suggest that disparities in fetal
neurobehavior are likely to cause postnatal autonomic dysregulation.
Endogenous opiates are known to modulate autonomic regulatory function,
particularly respiration during sleep, and decrease arousability in adults (Kruger, 1995).
In infants, of the many psychophysiological symptoms of neonatal withdrawal, pediatric
sleep dysregulation appears to be a common concern, which may potentially surface due
to abnormalities in the serotonergic system (5-HT) of the medulla oblongata (Harper,
Kinney, Fleming, & Thach, 2000). Medulla oblongata is a brainstem region that is
primarily responsible for modulation of cardio-respiration and arousals under homeostatic
stress or the physiological challenges presented to maintain homeostasis similar to infants
exposed to high levels of neurotoxic substances, including opiates, alcohol, and tobacco,
who often exhibit circuitry abnormalities (Kinney et al., 2003; Kinney, 2005). Such a
deficiency is believed to pose a risk for Sudden Infant Death Syndrome (SIDS)
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particularly if infants are prenatally exposed to substances of abuse, according to Jones et
al. (2010) who further emphasize that opiate-exposed infants are at even higher risk for
SIDS compared to other conditions such as prematurity, alcohol and/or nicotine exposure,
and sleep apnea.
While there has been general consensus on the potential sleep-related developmental
risks associated with opioids, the effect of in-utero exposure to methadone as an
exogenous opioid on sleep-related arousal regulatory systems has not been studied yet.
However, in adults methadone users, the most commonly reported neurobehavioral
problem associated with methadone use is insomnia or the lack of sleep; and in pregnant
methadone users, this problem appears to exacerbate during the 3rd trimester when
mothers are likely to increase methadone dose due to increased permeability of the
placenta that makes the fetus an additional consumer of the maternal dose and causes the
mother to withdraw before 24 hours (Nanovskaya, Nekhayeva, Hankins, & Ahmed,
2008). During this same period, fetuses are also supposed to be adapting to maternal
sleep-wake patterns such that if the mother is suffering from insomnia, so is the fetus
(Janssen et al., 2011), which could result in an abnormal sleep organization or sleep
dysregulation in newborns (Symanski et al., 2002).
Sleep dysregulation has been associated with increased sleep fragmentation, which is
characterized by increased frequency and duration of wakefulness following sleep onset
and decreased active sleep (Troese et al., 2008), the phenomenon previously found by
Hayes et al. (2007) to be responsible for sleep debt or sleep deprivation, and is likely to
decrease the frequency and duration of arousal parameters following sleep onset
indicating a deficient arousal regulatory system. Among these outcomes, for example,
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prematurity seems to add to the degree of risk for sleep disorders as demonstrated in a
study by Hayes et al. (2007) on apneic pre-terms who tended to exhibit poor
cardiorespiratory integrity especially during periods of sleep, which indicates that
prematurity could pose a cardiorespiratory challenge during sleep and impact the sleep
architecture of such infants. Since prematurity is one of the neonatal outcomes associated
with opioid exposure, this finding adds to the hypothesis of this thesis that perhaps an
exposure to exogenous opiates such as methadone could result in similar sleep-related
neurodevelopmental abnormalities in neonates as early as from birth.
Since the arousal system is emergent developmentally at birth, this thesis examined
neonatal sleep architecture as early as first or second postnatal night to determine whether
sleep and arousal features differ in neonates with prenatal opioid exposure (i.e., maternal
methadone) compared to non-exposed, demographically similar infants. Quantitative
deficits in arousals and wake state were hypothesized to reflect neurobehavioral
instability in opioid-exposed infants in the pre-withdrawal period (Days 1 or 2 of life).
Additionally, it was secondarily hypothesized that opioid-exposed infants may show more
sleep fragmentation, e.g., shorter sleep periods as well as excessive arousability and
irritability on day 2 than day 1 of life due to the development of opiate withdrawal. In
addition, this study also explored the genetic factor that may contribute to the expression
of behavioral states and SM.
1.2.4. Pharmacogenomics of Methadone in Sleep Wake and Arousal
Regulation. As mentioned earlier, methadone primarily works as a µ-opioid receptor
(OPRM1) agonist meaning that it binds to and activates the OPRM1 receptors. One of the
many recurrently reported side effects of methadone treatment appears to be sleep
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disturbance, particularly insomnia, which calls for a close investigation of the
pharmacogenomics of such an association. A group of Taiwanese researchers (Wang,
Tsou, Chen, Chen, Ho et al., 2012) found an association of SNP in the OPRM1 gene to
the change-in-libido and insomnia side effects sometimes (p<0.009). The insomnia
finding was observed in methadone patients with the OPRM1 polymorphisms who had a
positive urine morphine test and who did not use benzodiazepine hypnotics indicating
that SNPs in opiate receptor genes may predict disturbed sleep regulation in adults.
One of the adverse outcomes of prenatal exposure to opiates has been sleep
disorder in pediatric populations and this association appears to be influenced by the
severity of NAS (O’Brien & Jeffery, 2002). In a collaborative effort of Tufts Medical
Center and Eastern Maine Medical Center, Wachman et al. (2013) along with our lab
investigated the effects of single-nucleotide polymorphisms in the mu-opioid receptor
type 1 (OPRM1) and catechol-o-methyltransferase (COMT) genes on NAS severity. Both
of these genes have been linked to neural circuitry for addiction, including opiate and
psychiatric risks. The dominant genetic model was used, which takes into account the
homozygotes for the major allele (e.g., AA) in one group while the collapsed
heterozygotes and homozygotes for the minor allele (e.g., AG/GG) in another group to
compare group differences in outcome variables, which in this study, were length of
hospital stay and need for NAS treatment in methadone-exposed neonates. The results
revealed that the infants with the OPRM1 118A>G AG/GG and the COMT 158A>G
AG/GG genotypes had shortened LOS and less need for NAS treatment compared to the
carriers of AA genotype, suggesting that the polymorphism in the COMT gene may play a
role in the variability of withdrawal severity in methadone-exposed neonates.
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One explanation proposed in this study for the observed results is that the variant
allele may cause an increase in binding affinity with beta-endorphin and a decrease in
protein expression for the OPRM1 gene (Bond, Laforge, & Tian, 1998). Similarly, COMT
gene transcribes COMT enzyme, one of the functions of which is to degrade or inactivate
catecholamines such as dopamine, epinephrine, and norepinephrine at the postsynaptic
cleft (Grossman, Emanuel, & Budarf, 1992). SNP in the COMT gene results in a valine to
methionine mutation at position 158 (Val158Met) rs4680 (Lotta, Vidgren, Tilgmann,
Ulmanen, Melen, et al., 1995). The Val variant catabolizes dopamine about four times
more and faster than methionine (Lachman, Morrow, Shprintzen, Veit, Parsia, Faedda et
al., 1996). However, the overexpression of Met variant in the brain (Zhu, Lipsky, Xu, Ali,
Hyde, Kleinman et al., 2004) consequently decreases the enzyme activity by about 40%
(Chen, Lipska, Halim, Matsumoto, Melhem et al., 2004) and results in an increased
dopaminergic stimulation of the post-synaptic neuron due to a higher synaptic dopamine
level following neurotransmitter release. So the SNP in this gene may cause reduction in
the enzyme activity and increase the levels of catecholamines, which may result in an
improved stress tolerance in these infants. Taken together, since NAS severity is
associated with sleep disorders, and SNP in the COMT gene is associated with the NAS
severity, this thesis study explored to see if there may be an association between the
allelic variation of the COMT gene and sleep organization in neonates. Only methadoneexposed neonates were assessed for this part of the study because the neonates in
comparison group did not have genetic data.
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1.3. Covariates: Periconceptional Absolute Alcohol Consumption
Alcohol is a known teratogen that severely affects fetal growth (Goh, Hutson,
Lum, Roukema, Gareri, Lynn et al. (2010). However, alcohol consumption during
pregnancy is not easy to detect due to the underreporting of such cases in general selfreported methods (Baña, Tabernero, Pérez-Muñuzuri, López-Suárez, Dosil et al., 2014;
Hayes et al., 2002; Troese et al., 2008). Therefore, meconium bioassay is used frequently
for assessing prenatal alcohol exposure. Bana et al. (2014) employed the techniques of
gas chromatography/mass spectrometry and liquid chromatography/tandem mass
spectrometry to detect drugs and markers of chronic consumption of alcohol in
meconium to assess this phenomenon. A prospective study was performed during a period
of 10 months among 110 infants assessing anthropometry, neuromuscular development
and determination of toxic substances in urine and meconium. Meconium analysis was
conducted to identify fatty acid ethyl esters (FAEEs) and ethyl glucuronide (Etg), which
are the known meconium biomarkers for prenatal alcohol exposure (Goh et al., 2010).
Participants were surveyed regarding the obstetric history, toxic habits, and employment
status. The results of early detection markers analyzed in meconium (FAEE >1000 ng/g
and/or Etg >50 ng/g meconium), showed that 34.65% of pregnant women consumed
alcohol during pregnancy, and 17% were positive for both markers. Among the positive
cases, 50% of those exceeding a FAEE's value of 5000 ng/g in meconium had low birthweight children. Notably, only 4.5% of this sample had reported occasionally drinking
alcohol. These findings indicate that pregnancy-related drinking is highly likely to be
under-reported and may complicate the investigation of isolated substance exposure in
humans.
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Extensive research involving both animal and human samples has demonstrated
that prenatal alcohol exposure results in injury to the developing brain and adverse
developmental consequences such as fetal alcohol syndrome (FAS), growth retardation,
CNS anomalies, developmental impairment of cognitive processing (Green et al., 2007),
and Due to the likelihood of under-reported incidents of alcohol use during pregnancy
particularly in the high-risk population (Guo et al., 2010), studying ethanol exposure as a
possible contributing co-morbid factor to opiates in population is warranted.
In our previous study, Hayes et al. (2007) found lifetime history of alcohol
consumption to be associated with sleep deprivation and lower sleep related arousals in
apneic preterm neonates who were treated for apnea with caffeine or methylxanthine, a
standard treatment protocol for pediatric sleep apnea. Additionally another of our study
by Troese et al. (2008) also found prenatal alcohol to be associated with sleep
fragmentation in otherwise healthy infants. Prenatal exposure to alcohol was found to
lead to poor sleep in another study by Pesonen, Räikkönen, Matthews, Heinonen,
Paavonen et al. (2009) that assessed 8-year-old children with sleep disorders through
actigraphic assessments for 7 consecutive nights and found that children exposed
prenatally to alcohol had a 2.9-fold (95% CI: 1.1 to 7.6) increased risk for having short
sleeps and 3.6-fold (95% CI: 1.3 to 10.0) increased risk for low sleep efficiency, which
are markers of sleep fragmentations. Importantly, these associations were not confounded
by sex, gestational length, prenatal and perinatal complications, asthma, allergies, or
parental socioeconomic status, and body mass index at 8 years.
In this thesis sample (n=58), the amount of alcohol consumed per binge before
pregnancy (i.e., AA/binge) was significantly higher (p = 0.006) for mothers in the
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methadone group. Even though this measure was not directly reported for the current
pregnancy, it was important to note that the pattern of historic alcohol abuse is a reliable
predictor of under-reported alcohol use during pregnancy (Bana et al., 2014; Hayes et al.,
2002). The effects of prenatal alcohol, therefore, provide a model for evaluation of the
impact of prenatal exposure in this study.
1.4. Hypotheses
Based on the studies and arguments presented above the following hypotheses
were proposed and tested in this thesis study.
1.4.1. Hypothesis 1: Behavioral States Integrity. Quantitative deficits in
arousals and wake state are hypothesized to reflect neurobehavioral instability in opioidexposed infants in the pre-withdrawal period. To test whether sleep, arousal, and SM
features differ in neonates with prenatal opioid exposure (i.e., maternal methadone
treatment for dependence; n=31) compared to non-exposed, demographically similar
infants (n=19), all-night, sleep studies, using videosomnography, were conducted on day
1 or 2 of life.
A secondary exploratory hypothesis was proposed that opioid-exposed infants
might show more sleep fragmentation (e.g., shorter sleep periods, excessive arousal and
cry) on day 2 than on day 1 of life due to the possible development of opiate withdrawal,
which often begins at or around 48 hours post-birth. No differences in the behavioral state
parameters were expected between day 1 and 2 in the outcomes of comparison infants. A
2 (infant age) x 2 (exposure groups) analysis of variance (ANOVA) model was used to
test the interaction. Day 1 (methadone-exposed = 18; comparison = 8) and day 2
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(methadone-exposed = 13; comparison = 11) infants were compared for group
differences.
1.4.2. Hypothesis 2: Genetic Corollaries of Behavioral States and SM.
Preliminary work from our laboratory has shown that withdrawal severity in NAS-treated
infants differs based on single nucleotide polymorphisms (SNPSs) or allelic variants in
the COMT (catechol-o-methyl-transferase) gene with minor allelic variants (AG or GG)
showing shorter LOS and a fewer medication than the carriers of the major allelic variant
(AA; Wachman et al., 2013). In this study, it was hypothesized that minor allelic
genotypes of the SNPs in the COMT gene of opioid-exposed neonates would show better
sleep organizational characteristics measured by sleep-wake, and SM parameters in the
pre-withdrawal sleep study. For this hypothesis, 20 of the 35 methadone-exposed
neonates were examined through saliva samples (Genotek OGR-250 kit with CS-1) for
the alleles of the COMT gene and associations among sleep-related variables (SM, sleep,
wake, and arousal parameters) in the early post-birth, pre-withdrawal period.
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CHAPTER 2
METHOD
2.1. Participants
A subset of Caucasian (>98%) mother-infant dyads (N=58; total 116) from our
longitudinal study (grant number: DA024806-01A2) of the University of Maine funded
by National Institute of Health (NIH) was extracted for this thesis study. Participants
consisted of pregnant women receiving the methadone maintenance treatment (MMT)
program pre- or post-conception along with their neonates (N=37 mother-infant dyads; 74
total). Mothers were recruited during the 3rd trimester of pregnancy from three sites in
Bangor: the Acadia Hospital’s Narcotics Treatment Program (NTP), Bangor Discovery
House, and Metro Treatment of Maine. A socio-demographically matched comparison
group of mothers and infants (N=21 mother-infant dyads; 42 total) was also recruited.
Both methadone-exposed and comparison groups were similar in demographic
characteristics including alcohol and tobacco use except for the opiate use.
2.1.1. Recruitment Sites. The majority of methadone-maintained expecting
mothers were recruited from the Narcotics Treatment Program (NTP) at the Acadia
Hospital, as well as the Discovery House Clinic and Metro Treatment of Maine in
Bangor, Maine. Acadia Hospital served as the primary recruitment site for methadonemaintained women, as it is the largest MMT in Penobscot County, serving over 600
patients, of which 300 are female and 15% are pregnant at a given time.
Participants in the comparison group were recruited from the Family Practice
Center (FPC) and Women Infant and Children (WIC) office in Bangor, Maine. The FPC
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provides services to over 30,000 outpatients annually, and has been demonstrated in pilot
data to be similar demographically and psychologically to the NTP sample in both
preliminary (Heller et al., 2013; Logan et al., 2012) and historical (Hayes et al., 2002)
data. Importantly, the FPC and WIC population have been shown in our laboratory to be
similar to the NTP sample with respect to alcohol and tobacco use.
2.1.2. Inclusionary and Exclusionary Criteria. Participants were pre-screened
for initial eligibility criteria based on their age, socioeconomic status, stage of pregnancy,
and present and past substance use. Inclusionary criteria required all prospective
participants to be English speaking pregnant women between the ages of 18 and 40 years
who, if enrolled into the Narcotics Treatment Program, were maintained on methadone
(suboxone disqualified), and were diagnosed according to DSM-IV as opiate-dependent
at the time of MMT entry. Consents to access pregnancy and birth-related medical
records were obtained by collecting HIPAA waiver from mothers on behalf of themselves
and their neonates. Use of tobacco products or alcohol in either sample did not disqualify,
neither did continued illicit drug use during pregnancy or following birth in the
methadone-exposed sample. Mothers with serious medical condition (e.g., cancer,
diabetes) or psychopathology were excluded from the study as such conditions may
adversely impact infant outcomes, and results may not be comparable to the rest of the
sample. Other exclusionary criteria included preterm labor (<35 weeks gestational age),
congenital fetal malformation, or severe obstetrical complications during delivery that
compromised infant survival. In addition, infants must not have scored higher than 8 in
the Finnegan scores, a diagnostic tool of neonatal abstinence syndrome (NAS) used by
NICU nationwide, on the night of neonatal data collection. Infants were expected to be in
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a stable environment such as the newborn nursery on the night sleep data was recorded. If
the first night video was not usable, the data collection occurred the second night with a
pre-established assumption that NAS symptoms start appearing within or after 48 hours
of birth. Any data collected beyond 48 hours for the methadone-exposed group, therefore,
was not included in this analysis.
2.1.3. Institutional Review Board Approval. This project acquired an approval
from the University of Maine’s Institutional Review Board (IRB) as well as Eastern
Maine Medical Center’s IRB. The study fulfilled all requirements for Health Insurance
Portability and Accountability Act (HIPAA) compliance.
2.1.4. Risks and Discomforts. There were no physical risks involved with
participating in this study. A little psychological risk was anticipated during the maternal
interview process. Therefore, the participants were adequately informed ahead of time,
and encouraged to let the interviewer know of any discomforts they experienced while
answering certain items of the assessment tools. If need arose, referral to psychological
services was available to such participants. No such incidence has happened to this date.
2.1.5. Benefits. No direct benefits to either the mother or infant were expected as
a result of participating in this study. Participants were made aware of the purpose of the
study and the main objective of their participation, which was to contribute to new
research about how the developing brain works. Upon request, summaries of individual
assessment or results of overall findings were provided. Mothers were encouraged to
share the results with their children’s pediatrician.
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2.1.6. Confidentiality. All records were kept private and separate from
identifiable information in a double-locked filing cabinet accessible only to the essential
study personnel. All data were coded with a unique identifier to protect confidentiality.
This study was further protected by a Certificate of Confidentiality from the National
Institutes of Health. With this Certificate, study staff cannot be forced to give identifying
information to any federal, state, or local civil, criminal, administrative, legislative, or
other proceedings, even with a court subpoena. The researchers would use this certificate
to resist any demands for information that would identify study participants, although no
such circumstances arose.
2.1.7. Compensation. For this part of the project, participants received a total
sum of $175.00 compensation upon completion of the entire protocol. Of the total
amount, $100 was awarded upon completion of the maternal interview during the 3rd
trimester, and $75 for assessments conducted during the newborn hospital stay that
included overnight recording of the neonatal sleep, actigraphic data collection (data not
included in this thesis), and mother-infant saliva collection for genetic study. Saliva
specimens were also collected during the follow-up visits in case of an inability to collect
them during the hospital stay.
2.1.8. Voluntary Participation. Participants were informed during the initial
interview that their participation to the research is voluntary meaning they have the rights
to decide whether they want to participate in the study or withdraw from it any time
during the course of this study. This aspect of the study was emphasized repeatedly
during any other follow-up visits in order to make sure that the participants fully
understood their rights as research participants.
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2.2. Materials and Measures
Both mothers and infants were assessed using multiple IRB-approved tools for
this thesis project.
2.2.1. Maternal Assessments. The purpose of the maternal assessment was to
screen for any pregnancy or pre-pregnancy drug and alcohol history, and to collect
sociodemographic and psychological status at the time of enrollment.
2.2.1.1. Drug and Alcohol Use Measurement. A semi-structured clinical interview was
conducted to quantify licit and illicit drug use that occurred before or during the current
pregnancy. Quantity-Variability-Frequency (QVF; Jacobson, Jacobson, Sokol, Martier, &
Ager, 1993) method was used to measure all current and past substance use in which, the
mother was asked to report use of various substances retrospectively (before conception)
and currently (during the 3rd trimester), by detailing the quantity, frequency, and
variability of substance use during a typical week. Pregnant participants were asked to
describe to the interviewer how many drinks, what size drink, and what type of drink they
would consume on a typical Friday night, and these questions were repeated for other
days of the week. Participants were then asked the same series of questions about their
alcohol use during pregnancy. These participants were also asked if they sometimes
drank more than 5 glasses of beer, wine, or liquor as an assessment of binge drinking,
followed by questions to determine the frequency of binge drinking episodes within the
past year from the date of interview. They were also asked if they had any alcohol
dependence treatment history and for how long.
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In addition to the QVF, the Michigan Alcoholism Screening Test (MAST; Selzer,
1971) was also administered, which is a structured interview consisting of 25 yes/no
questions assessing both current and retrospective problematic alcohol consumption.
They include questions regarding participation in Alcoholics Anonymous, arrests for
drunk driving or drunken behavior, hospital admissions related to drinking, and loss of
employment or significant others as a result of drinking. The MAST has a good reliability
for detecting both lifetime history of problem drinking as well as recent past and current
use of alcohol (Zung, 1982). A clinical score of five affirmative answers was chosen from
the MAST as a cutoff indicative of problem drinking, as was recommended by the
developer (Selzer, 1971). The T-ACE (Russell, 1994), a 4-question screening tool
assessment of tolerance to alcohol also derived from the MAST, and the TWEAK
(Russell, 1994), a 5-question screening tool assessing alcohol dependence, were also
administered.
Additional alcohol use variables were calculated following a completion of the
interview. Alcohol use variables were calculated by determining the amount of alcohol
content in the type of alcohol the participant drank. Absolute alcohol (AA) was
determined using an algorithm based on the type of alcohol (e.g., beer, wine, and liquor
are assigned weighted multipliers), size of the container (e.g., number of ounces per
drink), and the number of drinks consumed during a sitting. Then AA was calculated by
multiplying the number of drinks by the number of ounces, the product of which was then
multiplied by the weighted multiplier for the type of drink. The AA estimate was then
used to derive other variables related to alcohol consumption, including average AA per
day (AA/D), AA per drinking day (AA/DD), and AA per binge (AA/binge).
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Following the attainment of alcohol information, participants were asked if they
had ever smoked marijuana. If so, they were asked to provide the age at which they first
used marijuana. They were then asked to determine the age at which their period of
heaviest use occurred as well as the frequency of use during that time period. Participants
were asked if they had used marijuana since becoming pregnant or before they knew they
were pregnant, and if so, asked to describe the frequency of use during pregnancy. This
series of questions was repeated for each of the opiates (heroin, methadone, oxycodone,
hydrocodone, codeine), cocaine and crack cocaine, barbiturates, sedatives and
tranquilizers (e.g., Valium, Xanax), amphetamines (including prescription
psychostimulants), methamphetamines, antidepressants, hallucinogens, and inhalants.
Participants were also asked at what age they began smoking, the number of cigarettes
per day currently smoked, the number of cigarettes per day they smoked at the beginning
of their pregnancy, and whether or not they had ever tried to quit. Copies of these tools
are attached in Appendix A.
2.2.1.2. Hollingshead Four-Factor Index of Social Status. Hollingshead 4-factor
Index of Social Status (Hollingshead, 1975) is a measure of socioeconomic status that
contains questions about general demographic information as well as data on education
and occupation of the participant and her partner. Education level and the type of
occupation are assigned point values (education = 1 to 7; occupation = 1 to 9). For the
weighted scores, education values were multiplied by 3 and occupation values multiplied
by 5; and the weighted scores were then added for the participant and her partner
individually before averaging them. The average was not computed if only one member
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of the family worked. For families in which neither partner worked, the score belonging
to the individual with the most education was utilized.
This measure was chosen because it is considered a more accurate portrayal of
socioeconomic status than income alone. Scores on this scale ranged from of 8 to 66 with
higher scores indicating better SES. The index was validated utilizing the 1970 US
Census such that the median years of school completed by the participants were
correlated by .83 and the occupation scores by .85. Additionally, median income earned
correlated by .78 and .67 with the occupation scores for men and women, respectively
(Hollingshead, 1975). Though unpublished, over 5800 articles have cited this index.
2.2.1.3. Peabody Picture Vocabulary Test – 3rd Editions (PPVT-III). The PPVTIII is a measure of verbal ability, which was chosen for its relatively short duration, ease
of administration, and validated use as a rough estimate of IQ (Dunn & Dunn, 1997). The
test consists of seventeen sets of twelve items each. For adults, the exam begins with set
thirteen, item number 145. Each item consists of a verb or noun to be matched with one
of the four pictures provided on the item page. The test administrator orally provides a
word to the participant and scores the right or wrong answer on the record form. The
assessment takes approximately fifteen minutes to administer and is intended for
individuals between the ages of 2 and 90+ years. The basal rule for this test is one or
fewer items wrong in the first age-appropriate set in order to proceed to the forward sets.
The discontinuation of test occurs upon eight or more incorrect answers in a single set.
This measure produces a raw score, standard score, stanine, percentile rank, normal curve
and age equivalent score. For this study, the standard score was used as an estimate of IQ
that can range from 40 to 160 with higher scores indicating better verbal ability. This
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measure has internal consistencies between .92 to .98, split-half reliability of .86 to .97,
alternate-form reliability of .88 to .96, and test-retest reliability of .91 to .94. The
established validity of verbal ability of PPVT-III correlation ranges between .69 to.74
with the OWLS scales, .91 with the WISC-III VIQ, .89 with the KAIT Crystallized IQ,
and .81 with the K-BIT Vocabulary (Dunn & Dunn, 1997).
2.2.1.4. Depression and Anxiety Measures. For the general assessment of
pregnancy-related depression, this study used the Beck Depression Inventory – 2nd
Edition (BDI-II; Beck, Steer, & Brown, 1996). This widely used twenty-one item selfreport tool assesses depressive symptoms. Participants are expected to accurately identify
and circle the number next to a statement that best describes their emotional or cognitive
state on each item over the past two weeks including the day of assessment. Total score
ranges from 0 to 63 with higher scores indicating greater depressive symptoms severity.
Even though the BDI-II does not have a cutoff score to indicate clinical depression, the
following guidelines are often used to interpret the total scores: minimal range 0-13, mild
depression 14-19, moderate depression 20-28, and severe depression 29-63; an internal
consistency for psychiatric patients is .86 and for non-psychiatric patients is .81 (Smarr,
2003).
Symptoms Checklist 90-Revised (SCL-90-R; Derogotis, 1983) is a screening tool
used for assessing a global distress in the areas of obsessive-compulsive thought,
somatization, depression, anxiety, hostility, paranoid ideation, phobic, interpersonal
sensitivity, and psychoticism. The symptoms are divided into three global indices: global
severity index (GSI), positive symptom distress, and positive symptom. The
questionnaire consists of ninety symptoms evaluated using a Likert scale (0=not at all to
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4=extremely), and participants are asked to rate how much they have been bothered by
each symptom over the past week including the day of assessment. The raw score derived
from the participants’ responses is then converted to a t-score. This measure rendered an
assessment of global psychological well being beyond the depressive symptoms assessed
by the BDI-II. Copies of these tools are attached in Appendix B.
2.2.2. Infant Assessments. Behavioral, medical, and demographic information
regarding the infants was collected at various time points using the following methods.
2.2.2.1. Infant Biomarkers. Infant biomarkers of substance exposure were
assessed during the hospital stay. Nurses from the NICU collected meconium samples
from the diaper in the first few days of life according to the established protocol, i.e.,
nurses collect approximately 5 gm of fecal material obtained from the first bowl
movements of the neonate (typically one diaper is sufficient), scrape the material from the
diaper, and store it in a specified standard label container to later send it to the Affiliated
Laboratories, Bangor, ME for screening of cocaine, opiates, cannabinoids, amphetamines,
and phencyclidine (PCP). This is a standard procedure for opiate-exposed infants in the
NICU at EMMC.
2.2.2.2. Finnegan Neonatal Abstinence Scoring System. This scoring system for
NAS (Kaltenbach & Finnegan, 1986) has been exclusively used as a standard
measurement of autonomic symptoms of withdrawal during the postnatal period. A score
was assigned every four hours by EMMC nursing staff during the infant’s hospital stay.
The study staff later obtained the daily scores from the medical record of the neonates
after they were discharged from the hospital. A copy of this tool is attached in Appendix
C.
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2.2.2.3. Videography. Infant sleep, arousal, and SM linked to emergent arousal
regulation and wake-sleep transitions (Giganti, Hayes, Akilesh, & Salzarulo, 2002;
Symanski, Hayes, & Akilesh, 2002) were monitored through an overnight videographic
sleep recording of neonates during the first or second postnatal night by using a SONY
DCR-SR82 camcorder that produced time-locked, digital, infrared videographic data of
maximum of 13 hours per neonate.
2.2.2.4. Behavioral States. Behavioral categories for coding neonatal sleep, wake,
arousal, and SM were derived from conventional methods used in previous research (e.g.,
Giganti et al., 2002; Symanski et al., 2002). To insure a fine-grained analysis of
behavioral arousal coding, types of arousal were analyzed using the following categories:
brief arousal (10-30 seconds), full arousal (>30 seconds and < 1 minute), and awakening
(>1 minute) which we have found to be representative of neonatal wake and sleep-sate
arousal behaviors. In order to assess sleep state arousal, it is essential to define the time
criteria for sleep as well. For this study, sleep was considered stable if a sleep bout lasted
longer than a minute following an onset. Within each sleep bout, behavioral observation
of SM bouts (if they occurred) were coded when the event lasted for greater than or equal
to 5 seconds (>5 seconds) post onset, and a latency of >5 seconds post offset was required
to determine inter bout interval as well as quiescence periods. Research Assistants blind
to the infant’s group status were trained to code behavioral states based on the
Developmental Neuroscience Laboratory’s training system beginning with familiarization
with the behavioral state coding methods of our laboratory for neonatal state coding
(Giganti et al., 2002; Hayes, Akilesh, Gilles, Fukumizu, Sallinen, et al., 2007; Symanski
et al., 2002;). Inter-observer reliability of >0.7 was established by using the Kappa
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coefficient method for each behavioral state: brief arousal, full arousal, wake, transition,
sleep, and SM separately.
2.2.3. Medical Record Access. Maternal medical records pertaining to current
pregnancy and delivery, and infant medical records from birth up to 1-month of age were
harvested after obtaining HIPAA consent from the participant during the interview.
Medical record data obtained included the date of induction into MMT, psychiatric
diagnoses, current and historical methadone doses, results of random UDS, date of entry
into prenatal care, and prescription drug use during pregnancy. Labor and delivery
measures were also obtained. Infant birth parameters such as gestational age, sex,
delivery type, birth weight and length, head circumference as well as onset of NAS
symptoms, pharmacological treatment for NAS, Finnegan scores, hearing screen results,
and feeding data were collected.
2.2.4. Saliva Samples. All DNA samples were collected using Oragene kits either
during the hospital stay or at the post discharge follow-up clinics of the same study.
Mothers were asked to spit in the Oragene GR-500 kit tube and the infant sample was
collected using an OG-250 DNA collection kit with CS-1 sponges. The maternal kit
contained a tube with marks for saliva quantity measurement and a lid with solution to
preserve the saliva. The infant kit included five cotton swabs, a pair of scissors, and
storage kit with solution to preserve the DNA from saliva and buccal cells. These kits
were ideal for this study as they were designed to store the collected specimen in the
room temperature for as long as 5 years.
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2.3. Study Design and Procedure
Participants were divided into exposed and non-exposed comparison groups.
Group 1 (n=37) comprised pregnant women who had been enrolled into a methadone
maintenance program (MMT) before or during the current pregnancy. Group 2 (n=21)
comprised a sociodemographically similar comparison mother-infant dyad group
recruited from the Family Practice Clinic as well as the Women, Infant, and Children
(WIC) office in Bangor, ME during the 3rd trimester; or at the time of birth while mother
and infant were hospitalized at the EMMC. Majority of the comparison mothers were
using nicotine during pregnancy. Therefore, cigarette smoking has been added in the
demographic characteristics of this sample.
2.3.1. Participant Recruitment Protocol. Prospective pregnant women were prescreened for the eligibility for the study based on the maternal inclusionary and
exclusionary criteria by graduate assistants or the PI either by phone or through a face-toface interaction. Prospective participants had to be Caucasian pregnant women from lowincome households with no known pregnancy complications at the time of prescreening
and no opioids present in the urine analysis. The exposure group participants had to meet
all these criteria in addition to being enrolled into the MMT.
2.3.2 Maternal Interview. Once the pregnant women met eligibility criteria and
agreed to participate in the study, a semi-structured interview was performed at our lab
space in Bangor, ME to collect maternal self-reported information regarding any prenatal
use of drug and alcohol. In addition, sociodemographic and physiological statuses of the
participants during the 3rd trimester of pregnancy were also collected. Informed consents
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for both mother and infant were obtained during this visit. Consent for HIPAA-approved
medical record access pertaining to current pregnancy and delivery for mother, and birthrelated information for infants was obtained. Maternal information on sociodemographic
background (Hollingshead), IQ (PPVT-III), depression (BDI-II), and anxiety (SCL-90R)
were also collected during this visit. The collected data were scored by our graduate
assistants in the lab at the University of Maine, and double scored by trained
undergraduate research assistants. All original files were de-identified and stored in a
double-locked cabinet in the PI’s office. The interview process took approximately one
hour and 15 minutes per participant and the participants were compensated with a $100
cash or equivalent gift card at the end of this visit.
2.3.3. Markers of Maternal Substance Use and Infant Exposure. Besides an
extensive prenatal maternal interview about a possible drug and alcohol use during this
pregnancy, infant exposure to maternal substance use was also measured through
neonatal meconium toxicology screens (MecSTAT-7) and urine toxicology screens upon
admission to the NICU and maternal urine toxicology screens after delivery. This
measure was useful for detecting possibly undetected poly drug use during pregnancy.
2.3.4. Neonatal Sleep Data (24-48 h Post-birth Pre-withdrawal Periods).
During the interview, information pertaining to possible delivery methods and tentative
due date was obtained from the mother. Our study team started contacting the newborn
nursery at the EMMC at least two weeks prior to due date twice a day to ensure no
missed opportunity of pre-withdrawal neonatal data collection. Mothers were also
requested to alert the study team about the birth within 12 hours post-birth if it occurred
before the due date. Cardiorespiratory monitoring was initiated immediately at birth in
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study participants and NAS scoring was initiated upon the coding of the first Finnegan
score >8. With a purpose to collect quality videographic data, parents were
requested/encouraged to house their neonates in the newborn nursery on the night of
videographic data collection. However, parental wish was equally respected, which
resulted in some variability in the location of recording such as mother’s room, newborn
nursery, or continuing care nursery (CCN). If the first night of data collection was not
successful, they were collected on the second night. Hence data resulted in the recording
time of 24-48 postnatal hours.
The study team went to the newborn nursery around the time of evening shift
change in order to avoid family visiting hours and to personally assure that the night
nurse for the participant was fully informed of the study conditions. A SONY DCR-SR8
camera was set up on a sturdy tripod next to the infant’s bassinet with the camera view
focused to cover at least the upper half of the body, and the recordings of nocturnal sleep
period (midnight to 0500) were collected, which formed the basis for sleep, arousal and
SM analyses. Midnight to 5AM was deemed the most optimal time as the environment
tended to be much quieter with significantly less interruption occurring. Nurses were
asked to use cluster care (i.e., disturb infants only as needed and for feeding during the
night recording period). Finnegan scores were tabulated by the attending nurse following
the feed and were inclusive of the previous 4h-interval as was normally done. If scores
suggested active abstinence (>8), the departmental directive required scoring every 2 h.
The main purpose of the Finnegan score in this study was to determine that the infant’s
status was pre-withdrawal during the recording period.
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2.3.4.1. Videographic Data Processing. Each baby had approximately 13 hours of
video, which was the maximum capacity of the camera memory card. The camera and
other equipment were collected the next morning from the newborn nursery at EMMC
and brought to our University lab to download the video in the external hard drives. If the
first night data was spoiled, data was collected the second postnatal night using the same
procedure as the first night. Once the download was complete, the time stamp for
midnight was calculated using an Excel spreadsheet and the segment from midnight to 5
AM (0000-0500) was trimmed for behavioral state analysis.
2.3.4.2. Behavioral States Coding. Trained and group-blinded undergraduate RAs
coded and double-coded the videos using our lab computers. Coding criteria for sleep,
wake, arousal, and SM were adapted from our previous studies mentioned below.
2.3.4.2.1. Coding Protocol. The following coding criteria were derived from
Giganti et al. (2002); Hayes et al. (2007); and Troese at el. (2008), with primary reference
to Behavioral State Criteria stated in Tohman et al. (1985).
Sleep. Sleep is generally divided into active and quiet types depending on the
behavioral and physiological characteristics. For this sample, however, it was not possible
to separate the types of sleep due to the nature of the videographic data that was
influenced by environmental factors in the newborn nursery. Therefore, the sleep was
coded when an infant’s eyes were shut; motor activity was either low or sporadic with
muscle tone remaining low. Occasional mouthing and grimacing behaviors as well as SM
may or may not have occurred. These characteristics were expected to persist longer than
a minute (>60 secs) to be coded as sleep in this sample. Otherwise, the sleep-like
behavior was coded as either indeterminate or whatever state the baby was in before the
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initiation of such a behavior. Even though an identification of respiratory variability is
important in characterizing behavioral states, it was difficult to detect respiration in this
sample as the babies were swaddled for the most part of the videos. Therefore, the quality
of respiration was not included while characterizing the sleep and wake states.
Wake. Wakefulness is an alternate state of sleep. The process of awakening
mostly involves - but may or may not be preceded and followed by - transition events.
For this study, wakeful state was coded when the infant’s eyes were mostly open,
focused, and may have been scanning the environment. This state was expected to
include crying and fussing with high or low motor activity tracked by regular respiration.
Sometimes the baby’s eyes were not expected to be open or just one eye would have been
open due to the environmental factors such as lighting and position. In such a scenario,
the coder had to take into account other behavioral characteristics that met the criteria for
a wake state. These characteristics, if continued for longer than a minute (>1 minute) was
considered a wake state. The event with these characteristics, if lasted for less than a
minute, was counted as an arousal.
Sleep State Arousals. Arousal was coded when it occurred within sleep bouts, and
had, in addition to partial or full eye opening, all or either of the characteristics such as
general body movements, increased heart rate, occasional grimacing, and cry or fuss. The
neonate was usually expected to return to sleep state after this event but sometimes was
intervened by a nurse especially if the neonate was crying or fussing. Depending on the
duration of the event, arousal was divided into two categories: brief arousal for which,
these characteristics had to last from 10 to 30 seconds, and for full arousal, greater than
30 seconds up to 60 seconds.
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Nurse Intervention. For our sample, nurse intervention was characterized by the
presence of an adult hands/arms/body in the camera view for longer than or equal to 5
seconds (>5 secs) touching the baby, which may or may not have initiated or caused a
change of state. Nurse intervention was coded for two categories: (1) within state
intervention: an adult hand or body appeared in the camera view for at least 5 seconds to
medicate or adjust the baby when the baby was within a stable sleep or wake state; (2)
state changing intervention: an adult hand or body appeared in the camera view for at
least 5 seconds, touched the neonate, and caused a state change (e.g., sleep to wake).
Transition. Transition event was expected to precede or follow sleep and wake
states, and could include any of the characteristics such as SM (sleep-to-wake transition),
yawn, drowse, and/or grimaces. SM or grimaces that occurred during a sleep bout and did
not lead to the baby’s awakening were not coded as transition. Transition was considered
ended when the baby achieved a stable state (i.e., awake or sleep) according to the states
criteria.
Indeterminate. A state was coded indeterminate if the neonate was showing signs
of mixed states characterized by oscillation between sleep- or wake-like states for at least
10 seconds without any distinctive transition to a different state occurring. For example,
if a neonate was drowsing and/or grimacing with excessive head and body movements in
the middle of a sleep or wake bout that looked like a transition but the neonate failed to
transition to the next state and instead retained the preceding state, such a bout was coded
as an indeterminate state, which is also named disorganized sleep in a study by Field,
Diego, Hernandez-Reif, Figueiredo, Schanberg, and Kuhn (2007).
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Cry. Frequency and duration of cry utterances were measured. Even though cry
behavior bears a range of characteristics (LaGasse, Neal, & Lester, 2005), only the
vocalized cries were recorded in this study due to methodological constraints. Cry events
were recorded with 5 seconds of forgiving period between two bouts. For example, if two
or more cry bouts occurred with less than a 5-second-gap in between, the whole set of
bursts was coded as one whole bout. Cry has similar physiological characteristics to
arousals or awakenings with an exception of difference in the pitch of vocalization
(LaGasse et al., 2005). Therefore, the cry bouts that occurred within a sleep bout that met
the duration criteria for brief arousal, full arousal, or awakening were also added in
calculating the frequency and duration of arousal and awakenings.
No baby. In overnight videographic data, one issue we faced was losing sight of
the neonates because they might have been taken away from camera view for multiple
reasons such as for feeding, changing, or cuddling (if the neonate was distressed). In this
study, the primary target length of video data for each neonate was 5 hours (2400-0500h)
but many of the videos in the current sample had sections in which the infant was taken
away from camera view or the camera was shut off for during parts of the recording
period. This issue was problematic in consistently calculating the average duration and
frequency of events that occurred within the 5-hour period. Therefore, the length of each
video clip during which the neonate was removed from the camera view for two or more
minutes was coded as “no baby,” and the total duration of the segment with missing data
was subtracted from total video duration of each neonate before obtaining the average
frequency and duration measures.
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2.3.4.3. SM Coding. After isolating the sleep bouts of neonates from midnight to
5 AM video segments, the sleep bouts were coded by our group-blinded RAs for SM bout
frequencies and durations using an Excel template developed in our Developmental
Neuroscience lab. The criteria for coding SM were adopted from our previous lab works
(e.g., Hayes & Mitchell, 1998; Hayes, Plante, Kumar, & Delivoria‐Papadopoulos, 1993;
Hayes, Plante, Fielding, Kumar, & Delivoria‐Papadopolos, 1994) and also from Prechtl
(2001). The characteristics included neonatal writhing gross motor movements with a
variable sequence of arm, leg, neck, and trunk movements within a sleep bout to last
greater than or equal to five seconds (>5) with a 5-second of forgiving time in between
two bouts. If two such bouts occurred within less than 5 seconds, it was considered one
whole bout. Quiescence was coded when the neonate remained immobile between offset
of one SM bout and the onset of subsequent SM bout within a single sleep event duration
for greater than or equal to 5 (>5) seconds with the exception of occasional twitches or
mouth movements (e.g., Hayes et al., 1994). Additionally, inter-bout interval (IBI) was
calculated to gauge the lapse of time between two or more bout onsets within single sleep
event duration. The observational coding task for the RA’s involved identifying and
recording on the coding template the onset and offset of each SM bout. The template then
rendered the total duration and frequency of SM bouts. The template was also formatted
to compute the frequency and duration of quiescence and IBI. The outputs were imported
to an SPSS file and further computed for the average bout duration, frequency per sleep
bout, and proportion to total sleep time spent on each of the variables (i.e., SM,
Quiescence, and IBI).
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2.3.5. Genetic Data Processing. Since neonates tend to have dry mouth, the
inside of their cheeks were swabbed and the swab heads were then secured in the OGR250 kit for assaying. Mothers were asked to spit in the tube provided by the OGR-500 kit
and the tube was securely tightened after the saliva was mixed with the storage fluid.
These specimens were stored at room temperature before sending to Tufts Medical Center
for DNA extraction. Once the specimen arrived Tufts Medical Center Clinical and
Translational Research Center Core Laboratory for processing, DNA was isolated and the
regions of interest were genotyped for the following five main SNPs: 118A>G
(rs1799971, dbSNP database; assay C_8950074_1) within the OPRM1 gene; 3435C>T
(rs1045642, dbSNP; assay C_7586657 _20), 2677G/T/A (rs2032582, dbSNP; assays
C_11711720C_30 and C_11711720D_40), and 1236C>T (rs1128503, dbSNP; assay
C_7586662 _10) within the ABCB1 gene; and 158A>G (rs4680, dbSNP; assay
C_25746809_50) within the COMT gene, using established Taqman technology
(Wachman et al., 2013). For this thesis study, only 158A>G (rs4680, dbSNP; assay
C_25746809_50) within the COMT gene was analyzed using the dominant model (AA vs
AG/GG).
2.4. Data Analysis
2.4.1. Calculation of Event Frequency and Duration of Behavioral States and
SM Parameters. For the analysis of behavioral states and SM parameters, the most
commonly used method in our lab is the calculation of frequency and duration of
individual states, the averages of which are then analyzed for overall analysis. However,
every neonate presents with a variable set of behavioral patterns as well as the amount of
time spent on each behavior. In addition to these obstacles, in the videographic data of
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this study, the neonates were not always positioned in the most desired way, and were
removed from the camera view at times that resulted in the fragmentation of total video
length and some missing video duration. In order to adjust for such variability in the
duration of total time per neonatal study, the total duration of “no baby” segments were
individually subtracted before computing the average frequency, average event duration,
and proportion of total time spend on an event for each observed behavior per neonate.
2.4.1.1 Average Event Duration Measure. Average event duration of each
observed behavior was obtained by dividing the total duration of each event or state by
the total frequency of corresponding event or state for each neonatal video.
Sum of Event Duration
= Average Duration (Sec)/event
Sum of Event Frequency

A combined average duration of full and brief arousal was also computed as a
composite measure of arousal in order to control for the variability in arousal parameter
across sample due to two separate arousal measures used in this study. The composite
average duration was computed by dividing the sum of total raw durations of brief and
full arousals by the sum total of raw frequencies of both measures for individual
neonates.
Sum of BA and FA Raw Durations
= Composite Arousal Duration
Sum of BA and FA Raw Bout Frequency
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2.4.1.2. Average Frequency Measure. For the frequency measure of behavioral
states, the raw sum of an event frequency total divided by total coded hour that rendered a
frequency of a state or an event per hour.
Sum of Raw Event Frequency
= Average Frequency/Hr
Coded Video Duration (Hour)

For the average frequency of SM and arousal parameters, total sum of the raw
frequency of SM, IBI, quiescence, BA, and FA bouts were individually divided by total
sleep bouts per neonate which provided an ‘average frequency per sleep bout’ measure
for SM and arousal parameters.
Sum of Raw Event Frequency
= Average Frequency/Sleep Bout
Sum of Total Sleep Event Frequency

2.4.1.3. Proportion Measure. Proportion of total coded duration spent on an event
was obtained for behavioral state parameters in order to measure how much of the total
time a neonate expressed a certain behavior. To obtain this measure, the duration sum of
sleep, awakening, nursing intervention, transitioning, and indeterminate state was divided
by total coded video duration in seconds individually for each neonatal sleep study.
Sum of Event Durations (Seconds)
= Proportion of Event Duration
Total Coded Video Duration (Seconds)
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The proportion measure of brief arousal, full arousal, as well as SM parameters
was derived by replacing the denominator of the above equation with the sum of total
sleep duration in seconds.
Sum of Event Durations (Seconds)
= Proportion of Event Duration
Total Coded Sleep Duration (Seconds)

2.4.2. Statistical Analysis. Data was analyzed using IBM Statistical Package for
the Social Sciences - Version 21 (IBM-SPSS-21) for Windows. Measures of maternal and
infant demographic characteristics as well as maternal drug and alcohol use were
analyzed for group differences in methadone and comparison by using independent
sample t-tests for continuous variables and chi-square for categorical variables. Each
state/behavior was categorized into average duration, frequency per hour/sleep bout, and
proportion of total coded time/sleep time categories (e.g., average sleep bout duration,
frequency of sleep per hour, and proportion of total sleep).
All behavioral state and SM measures were analyzed by using multivariate full
factorial general linear mode (GLM). The independent variables were contrasted for
difference. Factor interactions were displayed in means for overall interaction, betweenfactor interaction, as well as within-factor interactions. Main effects were computed with
confidence interval adjusted to LSD at 5% significance level. Homogeneity of variance
was analyzed using Levine’s test. After performing an exploratory analysis using
Pearson’s correlations and independent sample t-tests, AA/binge was found to be
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significantly different (p = 0.006) between the two exposure groups. Therefore AA/binge
was added in the model as a covariate.
Hypothesis 1 was tested using the abovementioned model on behavioral state
parameters (frequency and duration measures of sleep, wake, arousal, cry, nursing
intervention, transition, and indeterminate state) and SM parameters (frequency and
duration measures of SM, non-movement quiescence, and IBI).
For Hypothesis 2, allelic variants in the COMT gene were identified and divided
into AA and AG/GG groups according to the dominant model (e.g., Wachman et al.,
2013) and used as a two level factor in the multivariate full factorial GLM to test whether
polymorphisms in the COMT gene would influence the expression of SM and behavioral
states parameters.
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CHAPTER 3
RESULTS
3.1. Demographic Characteristics
Table 3.1 shows the summary of total participants used per study for this thesis.
The sleep study included 58 mother-infant dyads, of which 37 dyads were in the
methadone-exposed group and 21 were in the comparison group. Of the 58, a subset of 50
(methadone-exposed=31, comparison=19) dyads comprised the sample for behavioral
state analysis, 38 (methadone-exposed=25, comparison=13) for SM analysis, and 20
dyads (methadone-exposed =20) for the genetic study.

The 58 dyads were further divided into infant age categories - day 1 and day 2 based on neonatal age at the time of sleep recording. The methadone-exposed group had
21 neonates in the day 1 group and 16 neonates in the day 2 groups; and the comparison
group had 9 neonates in the day 1 group and 12 neonates in the day 2 group. Altogether,
this sample consisted of 30 one-day old neonates and 28 two-day olds.
3.1.1. Maternal Demographics and Substance Use. All mothers were assessed
during the 3rd trimester of pregnancy for periconceptional (i.e., before the knowledge of
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pregnancy) use of alcohol, tobacco and other substances of abuse. Mothers also provided
lifetime use maximum estimates of substances of use.

Table 3.2 shows group differences in maternal demographic characteristics that
were obtained by using parametric measure (independent sample T-test) for the
dependent variables or nonparametric measure (chi-square) for the independent variables
as deemed appropriate. Maternal demographic characteristics such as mother’s age at
infant birth, socioeconomic status (SES), verbal IQ (PPVT-III), prenatal depression (BDIII), global anxiety index (SCL-90-GSI), and number of cigarettes smoked per day during
pregnancy were compared between groups. Results revealed that the mothers from both
methadone-exposed and comparison groups were similar in age, SES, and PPVT-III, but
significant group differences were observed for BDI-II [t(54) = -2.29; p = 0.026] and
SCL-90R (GSI) [t(54) = -3.14; p = 0.003] measures. Most of the mothers across groups
smoked cigarettes during pregnancy (mean number of cigarettes/day: comparison = 2.50;
methadone-exposed = 9.20) but the methadone-exposed group mothers smoked
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significantly more cigarettes per day than the comparison mothers [t(55) = -4.15; p =
0.00].

The maternal sample was also compared for lifetime and periconceptional
use of drugs and alcohol by applying QVF measures for assessing frequency of use/week,
quantity of use each time and variability in the pattern of use per week. The maternal
samples were compared for pre-pregnancy lifetime use of drug and periconceptional use
of alcohol prior to the awareness of pregnancy and during pregnancy. The results, shown
in Table 3.3, reveal no group differences in TWEAK, T-ACE, AA/day, and AA/DD,
although the M group had non-significant but higher scores on these measures. The two
groups differed significantly for the following periconceptional alcohol measures: MAST
scores [t(54) = -2.13; p = 0.038], binge frequency per week [t(54) = -2.19; p = 0.033],
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and AA/binge [t(54) = -2.89; p = 0.006]. Specifically, the methadone-exposed group
scored higher than the comparison group on these measures. Mothers were also assessed
for lifetime use of other licit and illicit drugs. Group differences were analyzed for
cannabinoid use, other opioids besides methadone, cocaine, sedatives, and
antidepressants because both groups had some history of using these particular substances
out of all that were assessed. As shown in Table 3.3, the methadone-exposed group
showed significantly higher lifetime use of other licit and illicit drugs than the
comparison group [marijuana: t(54) = -2.57, p = 0.014; other opiates: t(54) = -6.98, p =
0.000; cocaine: t(54) = -3.91, p = 0.000; sedatives: t(54) = -3.89; p = 0.000;
antidepressants: t(54) = -2.21; p = 0.032].
3.1.2. Infant Demographics. Table 3.4. shows neonatal health parameters such as
length of hospital stay (LOS), gestational age (GA), birth weight (BW), and birth length
(BL), head circumference at birth (HC), and sex for all babies as well as NAS treatment
status for the methadone-exposed neonates only.
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The results revealed overall higher scores for the comparison group in LOS [t(55)
= 5.27; p = 0.00], GA [t(55) = 2.16; p = 0.04], and BW [t(55) = 2.16; p = 0.04]. LOS was
expected to be significantly different between groups because while comparison group
neonates go home by 2-3 days, methadone-exposed neonates must stay for 5 days
minimum and the LOS may prolong if they experience NAS. Even though GA and BW
were significantly different between the two groups, these variables did not have an effect
on the neonatal behavioral state outcomes (>.05) in the analysis of covariance.
3.2. Sleep Study
The sleep study for this thesis included 58 mother-infant dyads. The data was
analyzed for the frequency and duration of behavioral state categories (i.e., sleep, wake,
cry, transition, nursing intervention, brief arousal, full arousal, and indeterminate) and
primitive arousal categories (i.e., SM, quiescence, and inter-bout interval). Data was
analyzed using multivariate full factorial general linear model (GLM) with exposure
group and infant age (day 1 or 2) as independent variables to test Hypothesis 1
concerning behavioral state and quantitative arousal measures. As shown in Table 3.3,
AA/binge was used as a covariate in this and all GLM analyses as it differed significantly
between exposure groups in our sample and is an established teratogen. For Hypothesis 2,
restricted to methadone-exposed neonates, the frequency and duration parameters of
arousal and SM were examined using GLM model with the allelic variants of the COMT
gene (using the dominant model of allelic variants AA, AG/GG) as the independent
variable and AA/binge as the covariate.
3.2.1. Hypothesis 1: Behavioral States. It was expected in Hypothesis 1 that the
methadone-exposed group neonates would show quantitative deficits in wake and arousal
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regulation in relation to the Comparison group. Secondarily, it was hypothesized that
infant’s age on the day of recordings (day 1 or 2) would affect neonatal behavioral
outcomes. The direction of deficit was expected to be greater for the methadone-exposed
group on day 1 but increased on day 2 because of the fact that neonates with methadone
exposure could be experiencing early signs of NAS on day 2 of life and they might be
more prone to manifesting signs of sleep fragmentations. Hypothesis 1 included 50
(comparison = 19, methadone-exposed = 31) sleep studies for behavioral state analysis,
one per neonate. Table 3.5 summarizes the results. Behavioral state analysis revealed
significant findings for arousal and cry parameters using the GLM model described
above. A main effect of exposure group was observed for the average duration of brief
arousal [F(1,44) = 4.601, p = 0.038], as well as duration of the composite arousal
measures [F(1,44) = 5.262, p = 0.027]. Post hoc analyses revealed that the methadoneexposed group showed significantly more arousability than the comparison group
reflected in both brief and composite arousal measures (p < 0.05). A main effect of infant
age at recording (day 1 or 2) was also found, showing increased frequency of brief
arousals [F(1,44) = 4.920, p = 0.032], proportion of full arousals [F(1,44) = 4.301, p =
0.044], and frequency of full arousal [F(1,44) = 4.476, p = 0.040] on day 2 of life.
An interaction of exposure group and infant age was observed on the proportion
of full arousal measure [F(1,44) = 4.411, p = 0.041], explained by the methadoneexposed group showing a dramatic increase in arousability on day 2 (p<.05), not observed
in the Comparison group and interpreted as related to withdrawal.
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For infant cry, an age by exposure group interaction was found for relative
frequency [F(1,44) = 11.135, p = 0.002] and duration [F(1,44) = 9.293, p = 0.004]
measures. These results showed that the methadone-exposed group had significantly
higher sleep-related arousals (p < 0.05) as well as cry frequency (p < 0.05) and duration
(p < 0.05) compared to comparison neonates. Interestingly, the direction of change in the
duration and frequency of cry parameters was reversed in both methadone-exposed and
comparison groups such that even though the methadone-exposed group had higher
overall cry scores, comparison neonates were crying more on day 1 while methadoneexposed neonates showed an accelerated level of irritability characterized by increased
cry on day 2, which supports the secondary hypothesis of this thesis study that
methadone-exposed neonates are probably at risk for increased sleep fragmentation on
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day 2 due to potentially compromised sleep regulatory systems in utero. Such
hyperarousability in the methadone-exposed neonates may indicate that neonates were
withdrawing earlier than 48 hours. All other behavioral state parameters were not
significantly different between groups.
Since the methadone-exposed group showed an elevated rate of arousability and
irritability on day 2 of life, the behavioral states outcomes were further analyzed for the
methadone-exposed neonates only in lieu of genetic corollaries in an attempt to
understand the mechanism of primitive arousals in depth. Additionally, the effect of
genetics on the outcomes of SM measures was also explored.
3.2.2. Hypothesis 2: Genetic Corollaries of Arousal and SM. Neonatal SM and
arousal parameters were explored further to test Hypothesis 2 with a prediction that
polymorphism in the COMT gene would have a protective effect on neonates at the
presentation of homeostatic challenges during sleep. The directionality of outcome was
predicted to be higher for neonates with minor allelic variants (i.e., AG/GG) of the COMT
SNP genotypes. Of the 20 exposed neonates that had genetics data, 19 had the SM data
and 15 had the behavioral state data. Three in each of the behavioral states group and SM
group neonates had the AA genotype; and 16 in SM group and 12 in the behavioral states
group had the AG/GG genotypes. Analysis of full factorial multivariate GLM was
performed with SM and arousal parameters as dependent variables and AA/binge as a
covariate. The independent variable was the genotypes of COMT SNP gene that was
divided into two groups: AA genotype as one group, and AG and GG genotypes collapsed
into the second group. The genotypes in the second group are collapsed in order to
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minimize the variability of sample distribution between groups as G allele is believed to
occur less frequently in humans.
The results revealed a main effect of COMT alleles on SM duration [F(1,16) =
6.978, p = 0.018], quiescence duration [F(1,16) = 8.706, p = 0.009], and IBI duration
[F(1,16) = 10.048, p = 0.006]. The directionality of effect was as predicted such that
infants with the protective allelic variants (AG/GG) of the COMT SNP had significantly
higher SM in relation to neonates with the AA genotype. In the behavioral state measures,
a between-subject effect of COMT genotypes showed that neonates with AG/GG
genotype had lower average composite arousal duration [F(2,12) = 9.824, p = 0.003],
mean duration of full arousal [F(2,12) = 6.373, p = 0.013], mean cry duration [F(2,12) =
9.383), p = 0.004]; increased sleep frequency [F(2,12) = 12.198, p = 0.001] and mean
duration [F(2,12) = 4,784, p = 0.030] and proportion of sleep time [F(2,12) = 4.628, p =
0.032]; increase in the frequency of awakening [F(2,12) = 4.662, p = 0.032], and decrease
in the total awake time [F(2,12) = 4.628, p = 0.032] compared to neonates with AA
genotype. These results are further discussed in chapter 4.
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CHAPTER 4
DISCUSSION
Early markers of sleep disturbances indicate congenital neuronal deficits in the
arousal regulatory systems in the brainstem region. One of the functions of the brainstem
is cardiorespiratory regulation. Abnormality in this brain region as a consequence of
prenatal alcohol-exposure has been associated with SIDS (Athanasia, Karavasiliadou, &
Styliadis, 2011; Kinney, 2005). The purpose of this thesis study was to investigate
whether prenatal exposure to methadone, and other potentially under-reported substances
such as alcohol, could impact the neurodevelopmental integrity of a neonate that could
result in poor sleep quality as well as a deficit in the sleep-related arousal regulatory
systems. It was hypothesized that such deficits, if any, should manifest as early as 24 to
48 hours of life before the withdrawal from prenatal exposure. Finally, it was proposed as
an exploratory hypothesis that by day 2, impaired sleep may be present in the methadoneexposed group due to the development of NAS. The role of a genetic contribution to
sleep-wake, arousal, and SM was examined in hypothesis 2 in the methadone-exposed
neonates only. The polymorphism in the COMT gene, which our lab has shown affects
NAS severity, was found to also affect pre-withdrawal, neonatal sleep and sleep
movements
4.1. Behavioral States, SM, and Genetic Corollaries
In the Hypothesis 1, the methadone-exposed neonates were expected to have
arousal deficits in relation to the non-exposed comparison group neonates. We also
explored the effect of infant age (day 1 or 2) in these outcomes with an expectation that
the methadone-exposed neonates would show more sleep disruption, arousals, and cry
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bout on day 2 of life. Additionally, in the Hypothesis 2, the influence of a polymorphism
in the COMT gene on the sleep organization of the methadone-exposed neonates was
explored with an expectation to see that the carriers of the minor allelic variants would
have better sleep organization and robust SM compared to the carriers of the major
allele/This hypothesis relates to the findings by Wachman et al., (2013) that showed
better NAS neonatal outcomes for the carriers of the G allele.
4.1.1. Outcome Measures, Infant Age, and Exposure Group. One of the major
findings of this study was that the methadone-exposed group had an overall higher level
of arousability than the comparison group,. This result suggests that the sleep deficit is
related to sleep fragmentation (i.e., increased arousals per sleep bout), as we found with
alcohol-exposed infants (e.g., Hayes et al., 2007), rather than the deficit in arousal that is
seen once sleep fragmentation has led to sleep deprivation (e.g., Troese et al., 2008). This
association was influenced by infant age such that 2-day old neonates from the
methadone-exposed group, but not the comparison group, were more arousable and
irritable on day 2. The behavioral states of the comparison group remained relatively
stable on both days.
The hypothesis about arousal deficit due to sleep deprivation was influenced by
the findings from our previous studies as well as from the findings that revealed that the
neonates who succumbed to SIDS were suffering from an arousal deficiency (e.g., Kato,
Franco, Groswasser, Scaillet, Kelmanson et al., 2003), and that SIDS cases observed in
alcohol exposed infants were associated with an abnormality in the brainstem serotonin
system (Kinney et al., 2005), one of the functions of which is to regulate sleep and
arousal. Even though arousal deficit was not observed in the present study, significant
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signs of sleep disruption in the form of sleep fragmentation characterized by hyperarousability and crying during the night was seen in the methadone-exposed group but
not in the comparison group. Sleep fragmentation is the precedence for sleep deprivation
and arousal deficits as a function of sleep debt over time (Hayes et al., 2007).
The level of arousals showed main effects of group in which the methadoneexposed group was higher than the comparison group, and age, in which both groups
were higher on day 2. A significant interaction of group and age was also found that
showed that the arousal measures were similar across days for the comparison group, but
elevated for the methadone-exposed neonates on day 2. These findings do not clearly
support a pre-withdrawal brain injury in the methadone-exposed neonates. Nonetheless,
sleep fragmentation is clearly present in the methadone-exposed neonates by day 2 of
life. Hence, early in the post birth period, sleep fragmentation sets the conditions for
sleep deprivation as the methadone-exposed infants enter the withdrawal period after day
2. The prediction of arousal deficit in the methadone-exposed neonates at birth was not
found. However, the findings from this study do indicate that sleep fragmentation in the
methadone-exposed neonates is evident as a main effect of group. In early infancy, the
excessive propensity to arouse from sleep has been associated with poor sleep quality
(e.g., sleep disruptions and insomnia), which is known to impair daytime alertness and
performance in adults (Franco et al., 2010). Therefore, it is predicted that excessive
arousals due to sleep fragmentation in the methadone-exposed neonates will be
exacerbated through the withdrawal period, and the amount of arousals would likely
decrease to below the level of comparison neonates due to cumulative sleep debt during
the post withdrawal period.
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Hyperarousability and irritability that are generally observed in the NAS neonates
during NNNS assessments (Jones et al., 2010), our observation of a comparatively higher
rate of arousal and cry in the methadone-exposed group (p<.05) on day 2 of life may have
also resulted from the fact that withdrawal symptomatology for exposed neonates may be
surfacing earlier than expected by the physicians and nurses as reflected in the standard
NICU protocol which states that, on average, neonates take about 24 to 72 hours to
withdraw from the pre-delivery maternal dose of methadone (Hudak et al., 2012; Logan
et al., 2013). If this is the case, it provides evidence that neonates are suffering
withdrawal much earlier than is evident in the Finnegan withdrawal scoring method. The
methadone-exposed neonates may be challenged in terms of neurodevelopmental
adaptation to the environment for basic functions besides sleep such as feeding and social
interactions with the mother that is believed to begin immediately after birth (Fifer,
Byrdd, Kakua, Eigsti, Islerb et al., 2010). Fifer et al. (2010) suggest that neonates must
adjust their physiology and behavior to the specific demands of the novel postnatal
environment as fast as possible in order to insure survival. When neonatal sleep is
interrupted by excessive arousals and cry, the amount of restorative sleep is consequently
shortened leading to a compromised stress regulatory system. The hyperarousability and
irritability during the night-time sleep period observed in the methadone-exposed
neonates in the present study suggest that neonatal withdrawal may be evident by using
sleep quality as an important marker of withdrawal distress. Currently, sleep is one of the
ten markers of withdrawal, as is crying, but is a minor contributor to the assessment of
withdrawal severity in the Finnegan score. Earlier pharmacological intervention may be
afforded if sleep quality is seen as a marker for developing withdrawal. In future
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analyses, the relationship between Finnegan scores and sleep fragmentation for individual
exposed neonates in this study will be examined.
4.1.2. Maternal Psychiatric Health. Mothers in the methadone-exposed group
had significantly elevated psychiatric symptoms as indicated by the scores on depression
and anxiety measures during the third trimester (p < .05), which is known to compromise
the hypothalamic-pituitary-adrenal (HPA) axis of the fetus over time and potentially
permanently affect stress regulation in their offspring (Oberlander, Warburton, Misri,
Aghajanian, & Hertzman, 2006). Lifelong comorbidity of lower SES, addiction,
depression, and anxiety is well documented. In this study sample, it is possible that the
mother who suffered opiate addiction may have also suffered from elevated depression
and anxiety throughout the pregnancy and even before pregnancy; and the impact of
maternal psychiatric disease may have created an adverse epigenetic influence on their
offspring (Hein, Rauh, Engel, Häberle, Dammer, Voigt et al., 2014). Fetal exposure to the
combination of pharmacological and psychological stressors prenatally may compromise
the child’s long-term ability to modulate stress, and may affect adaptation over time. So,
it is possible that neonates were born exposed to excessive maternal stress through
psychiatric disease, maternal methadone, and other illicit substances, which are less often
seen in women in treatment, but are more common than in non-exposed comparison
infants.
4.1.3. COMT SNPS Genotype and Sleep Organization. The results for genetic
corollaries of SM and behavioral state parameters revealed that the carriers of protective
G allele (e.g., AG/GG genotypes) had comparatively more robust SM, less arousal and
cry, and increased sleep frequency and duration compared to neonates with the carriers of
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risk allele (e.g., AA genotype) indicating that the presence of G allele, previously shown
to be responsible for shorter NAS (e.g., Wachman et al., 2013), may also serve as a
protective factor against sleep disruptions.
Similar findings were observed in another study conducted by Gruber, Grizenko,
Ben, Gauthier, de Guzman, and Joober (2006) who investigated whether underlying
mechanism of sleep would be modulated by SNPs of the COMT gene of sleep-disordered
children. Thirty-four children aged 7-12 years who had a clinical diagnosis of ADHD
were assessed using actigraphic recordings. The results revealed that the children who
were carriers of the AA genotype showed poorer sleep regulation than those who carried
the AG/GG genotypes indicating that mutation in the COMT gene may influence
pediatric sleep organization as was observed in our study. These findings may provide a
partial explanation for the underlying mechanisms that may influence sleep state
organization of the methadone-exposed neonates in the present study.
COMT is an enzyme that deactivates dopamine, epinephrine, and norepinephrine
post-synaptically. Perhaps, the polymorphism in the gene producing this enzyme may
result in a decrease in the enzyme action on these catecholamines, thus, allowing excess
neurotransmitters to be available. Such increased availability of dopamine and
epinephrine may provide some advantage against neonatal opiate withdrawal in neonates
and mitigate the severity of NAS symptoms. For example, Wichers, Aguilera, Kenis,
Krabbendam, Myin-Germeys, Jacobs et al. (2007) studied 621 women to assess an
association between the subjective wellbeing and the polymorphism in the COMT gene.
They found that the ability of the participants to experience reward increased with the
number of G (Met) alleles. More interestingly, individuals with the val/val (AA) genotype
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experienced similar amounts of subjective well-being from a ‘very pleasant event’ as
met/met (AG/GG) individuals did from a ‘bit pleasant event’ indicating that the carriers
of AA genotype may have a diminished sense of well-being or perhaps the AG/GG
carriers may have an enhanced sensitivity to feel well. The findings suggest that the SNP
in the COMT gene may create a neurobiological environment that is more suitable for
producing positive affect as well as an increased ability to cope with stress. Future work
on the role of COMT SNPs in NAS is ongoing in our laboratory, but the sleep health
advantage in sleep continuity and robust sleep movements found for G carriers in my
study expands our understanding of the impact of polymorphisms in genes of addiction in
newborn withdrawal.
4.1.4. Perinatal Alcohol Effect. All significant outcomes observed in this study
were present in covariance with the total alcohol content that the mother used per binge
cycle before pregnancy (i.e., AA/binge). It is well known that alcohol is teratogenic (Guo
et al., 2010). Despite all the known fetal adversities, moderate consumption of alcohol
has recently been argued as safe during pregnancy in a large epidemiological study
(Humphriss, Hall, May, Zuccolo, & Macleod, 2013). Nonetheless, in an investigation of
moderate alcohol exposure on gene expression, Rosenberg, Wolff, El-Emawy, Staples,
Perrone-Bizzozero, and Savage (2010) conducted micro-array analysis of more than
28,000 genes in alcohol-exposed pups and found that the expression of 304 known genes
was altered two-fold or greater in the placenta from ethanol-consuming dams compared
with controls and about 76% of these genes were repressed in ethanol-exposed placentas.
The observed gene expression changes involved proteins associated with central nervous
system development, organ morphogenesis, immunological responses, endocrine
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function, ion homeostasis, and cardiovascular development, suggesting that even small
amounts of alcohol, that is most likely to go unreported (Baña et al., 2010; Hayes et al.,
2002), may alter the expression of a large number of placental mRNAs. Methadonedependent mothers are suffering from addiction and typically have a history of higher
alcohol intake than mothers who are not diagnosed with addiction. Hence, it is likely that
the mothers with opioid addiction and history of alcohol use may exert a compromised
epigenetic effect on their fetus by altering the ways in which their fetuses receive
methadone.
4.1.5. Primary Implications. Considering the significance of a burden NAS
poses on neonates, parents, care-providers, as well as policy-makers, a proper
pharmacological and clinical management of this condition is crucial. This thesis study
was conducted to examine pre-withdrawal status of sleep and arousal systems in a
controlled study. In the course of that effort, sleep fragmentation was found to be greater
in methadone-exposed infants, and that this impact was due to the likely emergence of
withdrawal on day 2. Further, amongst methadone-exposed neonate, polymorphisms in
the COMT gene were critical in predicting the level and severity of sleep fragmentation.
It is believed that the sleep-wake results are valuable in this regard because the sleep
parameters are likely early neurobehavioral markers of NAS that have not been reported
to date. Care-providers at the pediatric care facilities as well as the parents of such
neonates can benefit from such information by increasing their awareness of the at-risk
neonates’ behavioral patterns during sleep and by taking extra caution while observing
their neonates. Additionally, the duration and intensity of cry, arousals, and SM patterns
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observed during the pre-withdrawal period can be utilized in developing a protocol for
individualized treatment plan of the methadone-exposed neonates.
Since the results found in this thesis were present in covariance with prepregnancy consumption of alcohol (particularly binge), an accelerated effort to detect a
possible exposure of alcohol during pregnancy seems important. Similarly, a sustainable
support system for psychiatric conditions such as depression and anxiety particularly
among opioid dependent pregnant mothers could reduce the harm of methadone exposure
to some extent by allowing the developing fetus a relatively less adverse environment.
Finally, it would also be useful to identify additional genetic corollaries of NAS that may
be specific to certain symptoms, such as gastrointestinal, disrupted sleep continuity, and
other physiological as well as psychobiological symptoms to better predict the course of
NAS illness for the individual infant.
In relation to the outcomes of the comparison group, it is important to note that
the neonates in this group are considered high-risk as well because of their mothers’ low
SES and other maternal risk factors associated with poverty such as tobacco exposure and
maternal use of other substances such as marijuana. These risk factors influence prenatal
as well as postnatal outcomes of these neonates. Hence, the differences and similarities
observed in the outcomes of the comparison group are generalizable to a public health
population where health insurance is typically public, but are less generalizable to a
community sample inclusive of all income levels. Normative samples have been studied
by our group, which has established benchmarks for sleep parameters including deficits
in arousal and SM in typical neonates (Hayes et al., 1993, 1994, 1998, 2007) that serve as
a comparison for future work. The findings for the comparison group in the present study
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are comparable to our work with normative samples. The sleep-wake organization
findings with the methadone-exposed neonates are similar to other high-risk groups with
prematurity, alcohol or other prenatal exposures, with the exception of the identification
in the opiate sample of early opiate withdrawal on day 2.
4.2. Methodological Strengths and Limitations
The biggest strength of this thesis study is that it is the first human study assessing
arousals and SM of the methadone-exposed newborns as early as day 1 or 2 of life.
Another strength of this study is the identification of genetic corollaries that provides new
insight into risk and protective SNPs for sleep integrity in the early postnatal period.
Research in clinical samples presents significant risk of confounding factors as alternative
explanations for group findings. In order to minimize confounding influences, the
demographic characteristics of both methadone-exposed and non-exposed comparison
groups were matched as closely as possible through standardization of recruitment sites
and strategies across exposure groups, careful interview for psychiatric and substance
abuse patterns including urinalysis for all participants and similarities in age, SES and
mode of insurance. This resulted in the methadone-exposed group and non-exposed
comparison group having common backgrounds with the exception of opioid dependence
and the treatment with methadone. As a result, we were able to significantly reduce the
confounding factors such as maternal age, education, SES, ethnicity. Nonetheless,
important differences existed in periconceptual alcohol binge history, lifetime drug and
alcohol history, and psychiatric health during the pregnancy, discussed in more detail
below. Neonatal outcomes were differences in gestational age and birth weight but not in
other growth parameters.
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There were significant group differences in maternal characteristics such as
depression and anxiety as measured by BDI-II and SCL-90R, and tobacco consumption,
which, despite my and our lab’s efforts, were not controlled in this study due to sample
size and could not be added to model development. With regard to prenatal alcohol
measures, several alcohol measures were significantly different between the methadoneexposed and comparison groups. However, absolute alcohol per binge episode “before
the knowledge of pregnancy” was used as the alcohol covariate because it showed a
stronger association with exposure group. Therefore, the general linear model proposed
for this study was constrained to covary alcohol exposure because of our earlier work, but
future modeling may improve the solution, particularly for maternal depression and
anxiety markers as described above. Another noted methodological limitation of this
study was the inability of the examiner to control the quality of overnight neonatal video
data, which resulted in variability in the total coded time across the sample thus
warranting adjustment for lost data. Neonates were moved away from the camera
frequently, and the camera was occasionally turned off accidentally at night. Additionally,
babies were not facing the camera while sleeping in some cases, and this made it more
difficult to determine the behavioral states of these neonates.
Furthermore, despite a continuous effort of the investigator to train the coders
over several months in depth, it is also to be noted that the measures used to code the
videos for both behavioral states and SM parameters still require additional confirmation
through intra-class correlation. Significant computational effort was applied to automate
and streamline data collection accuracy to reduce error but there may still be some
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undetected inter-coder biases that may have influenced the results. For future work, these
potential biases must be assessed.
In regard to the outcomes pertaining to arousals and cry during sleep, one possible
explanation for such high arousability in the methadone-exposed group may be the fact
that cry events within sleep that met the duration criteria for arousals were also calculated
as arousals besides separately being calculated for cry events. Crying has similar
underlying physiology as wake and arousals, and is thought of as a sub-state of wake
except it involves higher-than-normal acoustic characteristics (LaGasse et al., 2005).
Therefore, it was justified that neonatal cry occurring within a sleep state should be
considered an arousal or a wake event depending on the duration. However, since the
methadone-exposed group had higher cry bouts and, hence, appeared more aroused.
Future work will further examine the duration measures of arousal in relation to cry
features, which have been found to be disrupted in cocaine-exposed newborns (Zeskind,
& Lester, 2001).
Sample distribution across groups was another limitation of this study. Even
though the project included a total of 58 participants with sleep studies, the sample was
not evenly distributed for the methadone-exposed (n=37) and comparison (n=21) groups.
Our lab often has more exposed infant sleep studies as comparison infants are more
difficult to recruit and typically healthier so have less inter-individual differences than
exposed samples. Also, for hypothesis 2, the genetic study was small with only 20
participants, of which only 4 were the carriers of AA genotype, and may have impacted
the outcomes. Even though the ration of allelic distribution was similar to the distribution
of Wachman et al. (2013), the statistical method they used was more robust due to sample
83

size. I have more genetic and sleep study participants in process that I will be able to add
to my dataset in the future. It is also important to note that the infant age in this study was
cross-sectional, and the differences in outcomes observed on day 1 and 2 included
different neonates in each group. Therefore, the results may have been influenced by
individual differences of neonates in each group. Longitudinal assessment of sleep is
suggested for the future studies.
The group differences in maternal depression and anxiety were not included due
to power constraints, and represent another limitation of this study. The association of
depression and anxiety to sleep disruption is well documented, and maternal depression
during pregnancy has been associated with neonatal sleep organization (Field, Diego,
Hernandez-Reif, Figueiredo, Schanberg, & Kuhn, 2007). In their study, Field et al. (2007)
assessed 253 women for prenatal depression and sleep disturbances during the 2nd and
3rd trimester, and observed their newborns during sleep. The depressed women reported
more sleep disturbances, higher anxiety, and elevated anger as well as elevated
norepinephrine and cortisol levels during both trimesters. The newborns of the depressed
mothers showed lowered deep sleep, more time in indeterminate (disorganized) sleep,
were more active and cried/fussed more. These symptoms indicate disrupted sleep that
may eventually lead to sleep deprivation. Given that these findings are similar to what
was observed in our results, and that our methadone-exposed group participants had
significantly higher depression and anxiety, it is possible that controlling for the
depression and anxiety measures may influence the outcomes of this study and need to be
included in future analysis.
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Gender of the neonates was another major factor that was not included in the final
analysis of this study. In this sample, 57% of in the methadone-exposed group and 95% in
the comparison group consisted of males. The gender difference in the comparison group
was significantly different (p=< .005). Given the findings of this study pertains to SIDS
risk, it is important to note that SIDS is more prevalent in males with consistent findings
of 50% male excess (Mage & Donner, 2014). Additionally, males and females have
different overall physiological profiles that may play a role in the expression of the
behavioral measures assessed in this study. For example, Kraemer (2000) summarizes in
his review why males are more at risk than female counterparts from as early as
conception. According to his review, “fragile males” are more vulnerable than females
even from conception, and male mortality is greater than female mortality throughout
life. Therefore, gender difference in the exposed neonates is an important uncontrolled
variable that may provide important results for the model of prenatal injury, SIDS risk
and sleep development proposed in my study.
Lastly, it is worth noting that the genetic corollaries of behavioral states and SM
were only available and assessed for the methadone-exposed group. The comparison
group genetic data, if available, could have provided us with an opportunity to assess an
interaction between the study groups and genetic variants in predicting the outcomes of
interest, thus broadening our understanding of an underlying genetic factors affecting
sleep organization.
4.3. Conclusion
This thesis study investigated the hypothesis that prenatal methadone exposure
may compromise neurodevelopment that may be indexed by analyzing sleep integrity and
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arousal properties during the pre-withdrawal period. Excessive increase in the
arousability and cry as well as a deficit in the average duration of SM measure were
observed in the methadone-exposed neonates, Additionally, the severity of such deficit
was further enhanced by genetic factors such that the exposed neonates carrying minor G
allele of the COMT gene, who are known to experience less severe NAS, showed
comparatively less arousability and irritability, more robust SM, and longer duration of
uninterrupted sleep than neonates without a G allele. Based on these observations, it is
hypothesized that the methadone-exposed neonates show poorer sleep integrity
characterized by sleep fragmentation, and show this difference from non-exposed,
comparison infants on day 2 of life. Hence, methadone-exposed neonates may be
experiencing sleep fragmentation related to opiate withdrawal earlier than 48 hours of
life. Finnegan scores measure stress abstinence, e.g., tremors, sweating, and diarrhea,
which generally not elevated during the sleep studies. Sleep fragmentation may represent
an early marker of NAS and may similarly adversely affect neonatal brain development if
not treated promptly. Therefore, to avoid such adversities, appropriate individually
modified treatment and management of NAS is recommended to reduce the potential
harm of prenatal methadone exposure. Disrupted sleep evidenced in this study may also
indicate a neurodevelopmental anomaly in the arousal regulatory system modulated
primarily by the medulla oblongata in the brainstem. The deficit in this area and an
altered arousal regulation have been linked to SIDS, thus, indicating that the reported
SIDS risk associated with prenatal exposure to opiates may be reflected in sleep
fragmentation in the neonatal period that is also associated with prenatal alcohol exposure
and the emergence of NAS.
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APPENDIX B: Finnegan Scoring Sheet
NEONATAL ABSTINENCE SCORING SYSTEM

Modified Finnegan Neonatal Abstinence Score Sheet1

Gastrointestinal Disturbances

Metabolic/ Vasomotor/
Respiratory Disturbances

Central Nervous System Disturbances

System

Signs and Symptoms

Score

Excessive high-pitched (or other) cry < 5 mins

2

Continuous high-pitched (or other) cry > 5 mins

3

Sleeps < 1 hour after feeding

3

Sleeps < 2 hours after feeding

2

Sleeps < 3 hours after feeding

1

Hyperactive Moro reflex

2

Markedly hyperactive Moro reflex

3

Mild tremors when disturbed

1

Moderate-severe tremors when disturbed

2

Mild tremors when undisturbed

3

Moderate-severe tremors when undisturbed

4

Increased muscle tone

1

Excoriation (chin, knees, elbow, toes, nose)

1

Myoclonic jerks (twitching/jerking of limbs)

3

Generalised convulsions

5

Sweating

1

Hyperthermia 37.2-38.3C

1

Hyperthermia > 38.4C

2

Frequent yawning (> 3-4 times/ scoring interval)

1

Mottling

1

Nasal stuffiness

1

Sneezing (> 3-4 times/scoring interval)

1

Nasal flaring

2

Respiratory rate > 60/min

1

Respiratory rate > 60/min with retractions

2

Excessive sucking

1

Poor feeding (infrequent/uncoordinated suck)

2

Regurgitation ( 2 times during/post feeding)

2

Projectile vomiting

3

Loose stools (curds/seedy appearance)

2

Watery stools (water ring on nappy around
stool)

3

AM

PM

Comments

Total Score
Date/Time
Initials of Scorer

1. Finnegan LP. Neonatal abstinence syndrome: assessment and pharmacotherapy. In: Nelson N, editor.
Current therapy in neonatal-perinatal medicine. 2 ed. Ontario: BC Decker; 1990.
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The NAS score sheet lists 21 symptoms that are most frequently observed in opiate-exposed infants. Each
symptom and its associated degree of severity are assigned a score and the total abstinence score is
determined by totalling the score assigned to each symptom over the scoring period.

Key points
The first abstinence score should be recorded approximately two hours after birth or admission
to the nursery (baseline score). This score reflects all infant behaviour up to the first scoring
interval time point.
Following the baseline score all infants should be scored at 4-hourly intervals, except when high
scores indicate more frequent scoring.
The score sheet allows for 2-hourly scoring over the 24-hour period.
A new sheet should be started at the beginning of each day.
Scoring is dynamic. All signs and symptoms observed during the scoring interval are included in
the point-total for that period.
If the infant’s score at any scoring interval is 8, scoring is increased to 2-hourly and continued
for 24 hours from the last total score of 8 or higher.
If the 2-hourly score is

7 for 24 hours then 4-hourly scoring intervals may be resumed.

If pharmacotherapy is not needed the infant is scored for the first 4 days of life at 4-hourly
intervals.
If pharmacotherapy is required the infant is scored at 2- or 4-hourly intervals, depending on
whether the abstinence score is less than or greater than 8 throughout the duration of
therapeutic period.
If after cessation of pharmacotherapy the score is less than 8 for the following 3 days, then
scoring may be discontinued.
If after cessation of pharmacotherapy the score is consistently 8 or more, then scoring should be
continued for the following 4 days (minimum) to ensure that the infant is not likely to develop late
onset of withdrawal symptoms at home following discharge.

Guide to assessment and scoring2, 3
The neonatal abstinence syndrome scoring system was designed for term babies on four-hourly feeds and
may therefore need modification for preterm infants. In a term infant scoring should be performed 30 minutes
to one hour after a feed, before the baby falls asleep.
If necessary the infant should be awakened to elicit reflexes and behaviour, but if the infant is woken to be
scored then diminished sleep after scoring should not be recorded. A crying infant should be soothed and
quietened before assessing muscle tone, Moro reflex and respiratory rate.

High-pitched cry

Score 2 if high-pitched at its peak, 3 if high-pitched throughout. Infant is
scored if crying is prolonged, even if it is not high-pitched.2

Sleep

This is a scale of increasing severity and a term infant should receive only one
score from the three levels of severity. A premature infant on 3 hourly feeds
can sleep for 2½ hours at most. Scoring should thus be 1 if the baby sleeps
less than 2 hours, 2 if less than 1 hour and 3 if the baby does not sleep
between feeds.2

Moro reflex

The Moro or startle reflex is a normal reflex of young infants and occurs when
a sudden loud noise causes the child to stretch out the arms and flex the legs.
Score if the infant exhibits pronounced jitteriness (rhythmic tremors that are
symmetrical and involuntary) of the hands during or at the end of a Moro
reflex. Score 3 if jitteriness and clonus (repetitive involuntary jerks) of the
hands and/or arms are present during or after the initiation of the reflex.
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Tremors

This is a scale of increasing severity and an infant should only receive one
score from the four levels of severity. Undisturbed refers to the baby being
asleep or at rest in the cot.2

Increased muscle tone

Score if excessive or above-normal muscle tone or tension is observed muscles become "stiff" or rigid and the infant shows marked resistance to
passive movements, e.g. if the infant does not experience any head lag when
being pulled to the sitting position; or if there is tight flexion of the infant’s arms
and legs (unable to slightly extend these when an attempt is made to extend
and release the supine infant’s arms and legs).4

Excoriation

Excoriations (skin abrasions resulting from constant rubbing against a surface
that is covered with fabric such as bed linen). Score only when excoriations
first appear, increase or appear in a new area.2

Myoclonic jerks

Score if involuntary muscular contractions which are irregular and exceedingly
abrupt (usually involving a single group of muscles) are observed.4

Generalised convulsions

In the newborn infant generalised seizures or convulsions are often referred to
as tonic seizures. They are most commonly seen as generalised activity
involving tonic extensions of all limbs, but are sometimes limited to one or
both limbs on one side. Unusual limb movements may accompany a seizure.
In the upper limbs these often resemble "swimming" or "rowing”. In the lower
limbs, they resemble "pedalling" or "bicycling." Other subtle signs may include
eye staring, rapid involuntary movements of the eyes, chewing, back arching,
and fist clenching.4

Sweating

Score if sweating is spontaneous and is not due to excessive clothing or high
room temperature4

Hyperthermia

Temperature should be taken per axilla. Mild pyrexia (37.2-38.3ºC) is an early
indication of heat produced by increased muscle tone and tremors.

Yawning

Score if more than 3 yawns observed within the scoring interval.2, 4

Mottling

Score if mottling (marbled appearance of pink and pale or white areas) is
present on the infant’s chest, trunk, arms, or legs.4

Nasal stuffiness

Score if the infant sounds congested; mucous may be visible.4

Sneezing

Score if more than 3 sneezes observed within the scoring interval.2, 4

Nasal flaring

Score only if repeated dilation of the nostrils is observed without other
evidence of lung or airways disease.4

Respiratory rate

Respirations are counted for one full minute. Score only if >60 per minute
without other evidence of lung or airways disease.2 Score 2 if respiration
involves drawing in of the intercostal muscles (retractions).

Excessive sucking

Score if hyperactive/disorganised sucking, increased rooting reflex, or
attempts to suck fists or thumbs (more than that of an average hungry infant)
are observed.3, 4

Poor feeding

Score if the infant demonstrates excessive sucking prior to feeding, yet sucks
infrequently during a feeding taking a small amount of breast milk or formula,
and / or demonstrates an uncoordinated sucking reflex (difficulty sucking and
swallowing).3 Premature infants may require tube feeding and should not be
scored for poor feeding if tube feeding is expected at their gestation.2

Regurgitation

Score if at least one episode of regurgitation is observed even if vomit is
contained in the mouth.4

Loose/watery stools

Score if loose (curds/seedy appearance) or watery stools (water ring on nappy
around stool) are observed. Check the nappy after the examination is
completed if not apparent during the examination.4
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APPENDIX C: Maternal Anxiety and Depression Tools
Study _________________________

ID __________
Date __ __ /__ __ /__ __ __ __

Symptom Checklist 90-R
Below is a list of problems and complaints that people sometimes have. Please read each one carefully
and enter the number that best describes how much you were bothered by that problem during the past
week.
Please enter only ONE.
FOR THE PAST WEEK, HOW MUCH WERE YOU BOTHERED BY:
Not At All

A Little
Bit

Moderately

Quite A
Bit

Extremely

1. Headaches

0

1

2

3

4

2. Nervousness or shakiness inside

0

1

2

3

4

3. Unwanted thoughts, words, or ideas that won't
leave your mind

0

1

2

3

4

4. Faintness or dizziness

0

1

2

3

4

5. Loss of sexual interest or pleasure

0

1

2

3

4

6. Feeling critical of others

0

1

2

3

4

7. The idea that someone else can control your
thoughts

0

1

2

3

4

8. Feeling others are to blame for most of your
troubles

0

1

2

3

4

9. Trouble remembering things

0

1

2

3

4

10. Worried about sloppiness or carelessness

0

1

2

3

4

11. Feeling easily annoyed or irritated

0

1

2

3

4

12. Pains in heart or chest

0

1

2

3

4

13. Feeling afraid in open spaces or on the streets

0

1

2

3

4

14. Feeling low in energy or slowed down

0

1

2

3

4

15. Thoughts of ending your life

0

1

2

3

4

16. Hearing words that others do not hear

0

1

2

3

4

17. Trembling

0

1

2

3

4

18. Feeling that most people cannot be trusted

0

1

2

3

4

19. Poor appetite

0

1

2

3

4

20. Crying easily

0

1

2

3

4
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Study _________________________

ID __________
Date __ __ /__ __ /__ __ __ __

FOR THE PAST WEEK, HOW MUCH WERE YOU BOTHERED BY:
Not At All

A Little
Bit

Moderately

Quite A
Bit

Extremely

21. Feeling shy or uneasy with the opposite sex

0

1

2

3

4

22. Feeling of being trapped or caught

0

1

2

3

4

23. Suddenly scared for no reason

0

1

2

3

4

24. Temper outbursts that you could not control

0

1

2

3

4

25. Feeling afraid to go out of your house alone

0

1

2

3

4

26. Blaming yourself for things

0

1

2

3

4

27. Pains in lower back

0

1

2

3

4

28. Feeling blocked in getting things done

0

1

2

3

4

29. Feeling lonely

0

1

2

3

4

30. Feeling blue

0

1

2

3

4

31. Worrying too much about things

0

1

2

3

4

32. Feeling no interest in things

0

1

2

3

4

33. Feeling fearful

0

1

2

3

4

34. Your feelings being easily hurt

0

1

2

3

4

35. Other people being aware of your private
thoughts

0

1

2

3

4

36. Feeling others do not understand you or are
unsympathetic

0

1

2

3

4

0

1

2

3

4

38. Having to do things very slowly to insure
correctness

0

1

2

3

4

39. Heart pounding or racing

0

1

2

3

4

40. Nausea or upset stomach

0

1

2

3

4

41. Feeling inferior to others

0

1

2

3

4

42. Soreness of your muscles

0

1

2

3

4

43. Feeling that you are watched or talked about by
others

0

1

2

3

4

44. Trouble falling asleep

0

1

2

3

4

37. Feeling that people are unfriendly or dislike you
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Study _________________________

ID __________
Date __ __ /__ __ /__ __ __ __

FOR THE PAST WEEK, HOW MUCH WERE YOU BOTHERED BY:
Not At All

A Little
Bit

Moderately

Quite A
Bit

Extremely

45. Having to check and double-check what you do

0

1

2

3

4

46. Difficulty making decisions

0

1

2

3

4

47. Feeling afraid to travel on buses, subways, or
trains

0

1

2

3

4

48. Trouble getting your breath

0

1

2

3

4

49. Hot or cold spells

0

1

2

3

4

50. Having to avoid certain things, places, or
activities because they frighten you

0

1

2

3

4

51. Your mind going blank

0

1

2

3

4

52. Numbness or tingling in parts of your body

0

1

2

3

4

53. A lump in your throat

0

1

2

3

4

54. Feeling hopeless about the future

0

1

2

3

4

55. Trouble concentrating

0

1

2

3

4

56. Feeling weak in parts of your body

0

1

2

3

4

57. Feeling tense or keyed up

0

1

2

3

4

58. Heavy feelings in your arms or legs

0

1

2

3

4

59. Thoughts of death or dying

0

1

2

3

4

60. Overeating

0

1

2

3

4

61. Feeling uneasy when people are watching or
talking about you

0

1

2

3

4

62. Having thoughts that are not your own

0

1

2

3

4

63. Having urges to beat, injure, or harm someone

0

1

2

3

4

64. Awakening in the early morning

0

1

2

3

4

65. Having to repeat the same actions such as
touching, counting, washing

0

1

2

3

4

66. Sleep that is restless or disturbed

0

1

2

3

4

67. Having urges to break or smash things

0

1

2

3

4

68. Having ideas or beliefs that others do not share

0

1

2

3

4
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Study _________________________

ID __________
Date __ __ /__ __ /__ __ __ __

FOR THE PAST WEEK, HOW MUCH WERE YOU BOTHERED BY:
Not At All

A Little
Bit

Moderately

Quite A
Bit

Extremely

69. Feeling very self-conscious with others

0

1

2

3

4

70. Feeling uneasy in crowds, such as shopping or at
a movie

0

1

2

3

4

71. Feeling everything is an effort

0

1

2

3

4

72. Spells of terror or panic

0

1

2

3

4

73. Feeling uncomfortable about eating or drinking
in public

0

1

2

3

4

74. Getting into frequent arguments

0

1

2

3

4

75. Feeling nervous when you are left alone

0

1

2

3

4

76. Others not giving you proper credit for your
achievements

0

1

2

3

4

77. Feeling lonely even when you are with people

0

1

2

3

4

78. Feeling so restless you couldn't sit still

0

1

2

3

4

79. Feelings of worthlessness

0

1

2

3

4

80. Feeling that familiar things are strange or unreal

0

1

2

3

4

81. Shouting or throwing things

0

1

2

3

4

82. Feeling afraid you will faint in public

0

1

2

3

4

83. Feeling that people will take advantage of you if
you let them

0

1

2

3

4

84. Having thoughts about sex that bother you a lot

0

1

2

3

4

85. The idea that you should be punished for your
sins

0

1

2

3

4

86. Feeling pushed to get things done

0

1

2

3

4

87. The idea that something serious is wrong with
your body

0

1

2

3

4

88. Never feeling close to another person

0

1

2

3

4

89. Feelings of guilt

0

1

2

3

4

90. The idea that something is wrong with your mind

0

1

2

3

4
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